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5ABSTRACT
The traditional treatment strategies for sensorineural hearing loss (SNHL) have not been
very satisfied. A cure for SNHL would thus depend on new technologies such as gene or
drug  delivery  using  nanocarriers  to  achieve  an  ideal  effect.  Nanocarriers  are  used  as
vectors in controlling drug release, protecting gene degradation by enzymes, and targeting
therapeutic delivery.  Nanocarriers, such as hyperbranched polylysine, liposomes and
poly(lactide-co-glycolide) (PLGA) carrying genes, drugs and fluorophores, have been
investigated in the inner ear. However there is no literature report on targeted inner ear
drug or gene delivery using nanocarriers. In this study, potential use of polymersomes
(PMs) and lipid nanocapsules (LNCs) as nanocarriers in rat inner ear respect to the inner
ear distribution, targetability and biocompatibility was investigated. Firstly, quenching
effect of copper sulfate (CuSO4) on autofluorescence and 1,1'-dioctadecyl-3,3,3'3'-
tetramethylindocarbocyanine-perchlorate (DiI)-encapsulated PMs were investigated. Then
the distribution of PMs and TAT (TAT-PMs) or Tet1 (Tet1-PMs) peptide functionalized
PMs in rat inner ear was detected; the effect of delivery methods on PM entering into the
inner ear was evaluated; and the distribution and biocompatibility of the LNCs in rat inner
ear were investigated.
In whole mounted specimens, autofluorescence was observed in the subcuticular
cytoplasm  of  inner  hair  cells  (IHCs),  the  OHCs,  the  SGCs,  the  strial  marginal  cells,  the
spiral ligament fibrocytes, the mesothelial cells of the scala tympani below the basilar
membrane, and the epithelial cells of the Reissner’s membrane. This autofluorescence
could be quenched by treatment of 1 mM CuSO4 (pH 5.0).  At the same time the CuSO4
treatment did not affect the fluorescence of DiI encapsulated in the PMs (p > 0.05,
Kruskal-Wallis test). Different delivery methods induced different distribution pattern of
the PMs: cochleostomy resulted in distribution of the PMs in the spiral ligament (SL),
mesothelial cells beneath Corti’s organ, supporting cells in Corti’s organ, and spiral
ganglion cells (SGCs); transtympanic injection induced uptake of the PMs in the SL and
mesothelial cells beneath Corti’s organ; topical round window membrane (RWM) surface
administration  showed  distribution  of  the  PMs  only  in  SL.  In  the  vestibulum,
transtympanic injection and cochleostomy induced more distribution of the PMs than did
topical RWM surface delivery (p < 0.05, Kruskal-Wallis test). TAT-PMs exhibited more
intense fluorescence signals in the RWM cells, spiral ligament fibrocytes, and mesothelial
cells beneath Corti’s organ than the scrTAT-PMs and the unlabelled PMs. Tet1-PMs were
detected in nerve fibers identified by the fact that Tet1-PMs were co-localized with NF-
200 immunostaining; however the ScrTet1-PMs and unlabelled PMs were remote from the
NF-200. LNCs were shown to pass though the RWM and reached the Corti’s organ, strial
vascularis  and  spiral  ligament  fibrocytes.  No  sigh  of  increased  toxicity  was  observed  in
the in vivo study.
6Both  PMs and  LNCs can  pass  through the  RWM and internalized  by  the  cochlear  cells.
Study of PMs showed that delivery methods affect the distribution of the PMs in the inner
ear cells. After transtympanic injection, more PMs were detected in the vestibulum than in
the cochlea, indicating that the PMs entered the vestibulum through the oval window.
Administration via cochleostomy displayed the broadest distribution of PMs in the inner
ear, because this method avoids the barriers between the middle ear and the inner ear. So it
is necessary to choose optimal delivery method according to the purpose of treatment. The
results suggest that enhanced permeability through the RWM can also be achieved by
using TAT peptide functionalized PMs. Further more specific targeting to the cochlear
nerve can be achieved by functionalizing the PMs with Tet1 peptides. Both PMs and
LNCs are potential nanocarriers to carry drugs and genes in the future to perform inner ear
therapeutics. The study of PMs and LNCs is still in its initial stage. More investigation of
the PMs and LNCs is needed in the future work.
7ABBREVIATIONS
BDNF:                 brain-derived neurotrophic factor
CPP:                    cell-penetrating peptide
CN:                      cochlear nerve
DAPI:                  4',6-diamidino-2-phenylindole
DiI:                      1,1’-Dioctadecyl-3,3,3’,3’-tetramethyl-indocarbocyanine perchlorate
DMF:                    dimethylformamide
EDTA:                  ethylenediaminetetraacetic acid
FDA:                    US Food and Drug Administration
FITC:                    fluorescein isothiocyanate
Gd-DOTA:           gadolinium- tetraazacyclododecanetetraacetic acid
GFP:                     green fluorescent protein
GT1b:                   trisialoganglioside clostridial toxin
IHC:                      inner hair cells
LNCs:                   lipid nanocapsules
MesothC:              mesothelial cells beneath Corti’s organ
MFNPs:                multifunctional nanoparticles
MRI:                     magnetic resonance imaging
NaCl:                    sodium chloride
NF-200:                neurofilament 200
NIH3T3:               mouse embryonic fibroblast cell line
OHC:                    outer hair cells
OSCs:                   outer sulcus cells
PBS:                     phosphate buffered saline
PCL:                     poly(?-caprolactone)
PEG:                     poly(ethylene glycol)
PEO-b-PCL:         poly(ethylene oxide)-block-PCL
PLGA:                  poly(lactide-co-glycolide)
PMs:                     polymersomes
rAAV:                   recombinant adeno-associated virus
RWM:                   round window membrane
ScrTAT-PMs:       scramble TAT conjugated PEG-b-PCL polymersomes
ScrTet1-PMs:       scramble Tet1 conjugated PEG-b-PCL polymersomes
SGCs:                   spiral ganglion cells
SGSCs:                 spiral ganglion Schwann cells
SL:                        spiral ligament
SLF:                      spiral ligament fibrocytes
SNHL:                  sensorineural hearing loss
SP:                        spiral prominence
8NaCl:        sodium chloride
SPIONs:   superparamagnetic iron oxide nanoparticles
ST:           scala tympani
StrMC:     strial marginal cells
StrV:        stria vascularis
SV:           scala vestibuli
TAT:        trans-activating transcriptional activator from human immunodeficiency virus 1
TAT-PMs: TAT functionalized PEG-b-PCL polymersomes
Tet1-PMs: Tet1 functionalized PEG-b-PCL polymersomes
TRITC:    tetramethylrhodamine isothiocyanate
TSF:         tractus spiralis foraminosus
TUNEL:   terminal deoxynucleotidyl transferase dUTP nick end labeling
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 1. INTRODUCTION
The human cochlea is deeply buried in the temporal bone, and access to it is limited by
membranous partitions. The blood-endolymph barrier hampers systemic application, and
delivered therapeutics can be cleared from the circulation by the immune system.
Traditional therapeutic methods of sensorineural hearing loss (SNHL) are not satisfactory.
Gene therapy and neurotrophin delivery are novel applications for the potential
regeneration or restoration of cochlear hair cells or cochlear neurons for the treatment of
SNHL. Multifunctional nanoparticles (MFNPs) are potential carriers of genes and
neurotrophins and may target specific inner ear cells, facilitating the treatment potential of
their contents. The first nanocarriers were developed in the 1950s, but they have been used
for therapeutic applications only for the past two decades (Petros et al., 2010). Drugs and
genes have been recently successfully encapsulated within the nanocarriers for the purpose
of prolonging the circulation time of the therapeutic and to protect it from enzymatic
destruction (Lamprecht et al., 2002; Song et al., 2009). Targeted delivery of nanocarriers
to specific inner ear cell populations can be achieved by functionalizing the nanocarriers
with peptides. For example, nerve growth factor-derived peptide-functionalized PMs can
specifically target CN and SGCs (Roy et al., 2010).
Nanocarrier delivery into the inner ear has been investigated using either systemic or local
delivery (Ge et al., 2007; Horie et al., 2011; Horie et al., 2010; Kopke et al., 2006; Thaler
et al., 2011; Zou et al., 2010b; Zou et al., 2011; Zou et al., 2010c). Gene expression in the
inner ear was detected first with liposomes and later with polymers as the delivery vector
(Jero et al., 2001; Tan et al., 2008). Liposome-based gene expression systems successfully
induced enhanced green fluorescent protein (eGFP) expression in mouse inner ear
following round window membrane (RWM) permeation (Jero et al., 2001).
Choosing an appropriate delivery method is necessary for efficient distribution of
therapeutic agents in the inner ear while minimizing adverse effects. Intracochlear delivery
appears to be the most effective method for delivering nanocarriers to cochlear cells.
Topical RWM surface delivery was moderately efficient, and systemic delivery has the
lowest efficiency (Tamura et al., 2005). The low delivery efficacy and the associated
adverse effects of systemic administration make this method not an ideal treatment for
inner ear diseases (Hoarau et al., 2004; Robey et al., 2010). A cochleostomy can be
performed only in certain circumstances as it can potentially result in inner ear damage.
Local drug delivery is now used extensively in the clinic for treating and diagnosing
diseases (Pyykkö et al., 2010; Robey et al., 2010).
There are two openings between the middle ear and the inner ear: the round window and
the oval window. The physiological function of these barriers is to prevent hazardous
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substances from impairing the inner ear cells. At the same time, however, they inhibit
passage of the therapeutics following intratympanic administration. The transport of
MFNPs across these barriers may potentially be facilitated by functionalizing nanocarriers
with  cell-penetrating  peptides,  such  as  trans-activating  transcriptional  activator  from  the
human immunodeficiency virus 1 (TAT) peptide.
The  purposes  of  the  present  study  were  to  1)  evaluate  the  efficacies  of  different  PM
delivery methods into the inner ear; 2) examining the ability of the cell-penetrating peptide
TAT-conjugated PMs; 3) determining the in vivo targetability of Tet1 peptide-
functionalized PMs and 4) examining the distribution and biocompatibility of lipid
nanocapsules LNCs the in rat inner ear.
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2. REVIEW OF THE LITERATURE
2.1 Overview of nanocarriers
2.1.1 Current status of the nanocarriers as therapeutic agents
The first generation of nanocarriers consisted of liposomes and polymers. Liposome or
polymer-drug conjugates were the foundation of advanced drug delivery using
nanocarriers (Petros et al., 2010). There are many types of nanocarriers nowadays:
liposome, polymersome, micelle, nanocapsule, hyperbranched polymer, nanogel and
porous silica nanocarrier (Fig. 1) (Cornelissen et al., 1998; Discher et al., 1999; Huynh et
al., 2009; Petros et al., 2010; Thaler et al., 2010; Yan et al., 2011; Zhang et al., 2011).
Nanocarriers were successfully loaded with drugs, DNA and siRNA to prolong circulation
time in the body and to protect the loaded therapeutic from enzymatic degradation
(Lamprecht et al., 2002; Song et al., 2009). Different types of nanocarriers have been
developed to treat different cancers, pain, and infectious, age-related and inherited
diseases (Chiang et al., 2010; Dong et al., 2010; Petros et al., 2010; Tamaki, 2009). To
reduce the adverse effects of treatment, the concept of specific targeting by nanocarriers
was introduced. Previously, antibodies and proteins have been conjugated to nanocarriers
to induce targeted delivery of drugs and genes (Manil et al., 1986; Vives et al., 1997;
Zhang et al., 2004). To reduce the size of nanocarriers, short peptides have been developed
for different targeting purposes (Kreuter et al., 1995). Cell-penetrating peptides have also
been designed to enhance the internalization and cellular penetration of nanocarriers
(Silhol et al., 2002).
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Fig. 1 Structure of nanocarriers
Higher nanocarrier internalization rates can be achieved by manipulating several aspects
of the carrier themselves and the treatment protocol. Factors that increase internalization
include a smaller nanocarrier size, a positive charge, higher nanocarrier concentrations,
longer incubation times and higher incubation temperatures (Desai et al., 1996; Harush-
Frenkel et al., 2007; Jiang et al., 2011; Panyam et al., 2002). Clathrin-mediated
endocytosis, caveolae-mediated endocytosis and macropinocytosis are the primary
internalization pathways of nanocarriers. The pathway by which the carrier enters the cell
depends on carrier type, surface charge, and surface modifications (Harush-Frenkel et al.,
2007; Jiang et al., 2011; Wadia et al., 2004). Studies of poly(ethylene oxide)-block-PCL
(PEO-b-PCL)  PMs  demonstrated  that  the  core/corona  structure  of  the  PMs,  which  is
determined by the composition of the hydrophobic and hydrophilic fractions, affects the
internalization pathway, whereas the PM size does not (Mahmud, 2005). Peptide-modified
nanocarriers are most likely internalized via caveolae-mediated endocytosis or
macropinocytosis (Del Pozo-Rodriguez, 2009; Oba, 2008; Wadia et al., 2004). When
clathrin- and caveolae-mediated endocytotic pathways are inhibited, internalization via the
macropinocytosis pathway is increased (Harush-Frenkel et al., 2007).
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2.1.2 Polymersomes
PMs were first developed in late 1990s, and the proposal was made that phospholipids
self-assemble into liposomes (Chiruvolu et al., 1994; Discher et al., 1999). PMs have quite
stable structure compared to liposomes; they are stable for up to several months at 4 ºC
and release their loaded drugs for up to 5 weeks at 37 ºC (Li et al., 2007). Unlike
liposomes, which self-assemble from low-molecular weight lipids, PMs self-assemble
from amphiphilic block copolymers, which consist of linked hydrophilic and hydrophobic
polymer chains. Amphiphilic block copolymers have various structures: diblock (Lee et
al., 2001), triblock, graft (Zheng et al., 2009) and dendritic (Jain et al., 2010) copolymers.
Amphiphiles can self-assemble into spherical micelles, rod micelles (Cornelissen et al.,
1998) and network phases (Jain et al., 2003). By manipulating the molecular weight of the
hydrophobic chain, the size of the PMs and the thickness of the lamella can be modified
(Niu et al., 2010). By manipulating the weight fraction of the hydrophilic in the
amphiphilic block copolymer, the morphology of the formations can be modulated
(Ahmed et al., 2004; Jain et al., 2003). The lamella of the PM is thicker than that of the
liposomes, and the aqueous core of the PM can be larger than that of the liposome. One
study demonstrated that the PM lamella can load up to 10 mol% of a hydrophobic
substance, and the structure is quite stable at room temperature (Ghoroghchian et al.,
2006a). PMs can be easily loaded with hydrophilic and hydrophobic molecules in the
internal cavity and within the membrane, respectively (Ghoroghchian et al., 2006a; Liu et
al., 2010).
There are three types of poly(ethylene glycol) (PEG)-based PMs based on their inner
surface: poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene oxide), PEG-b-
poly(L-amino acid)s and PEG-b-poly(ester)s (Adams et al., 2003). Polyesters, such as
poly(ethylene glycol) (PCL), poly(lactide-co-glycolide) (PLGA), poly(D,L lactide acid)
(PDLLA) and poly(lactide) (PLA), are generally used as the hydrophobic core of PEG-
based PMs (Adams et al., 2003; Rafat et al., 2010).
Poly(?-caprolactone)-block-poly(ethylene glycol) (PEG-b-PCL)  is  one  of  several  block
copolymers used to produce PMs (Ghoroghchian et al., 2006b). Poly (?-caprolactone)
(PCL) forms the hydrophobic membrane of the PM, and polyethylene glycol (PEG) forms
the hydrophilic corona. Both PEG and PCL are FDA (US Food and Drug Administration)
approved, biodegradable polymers used in medical applications (Davidoff et al., 2011;
Kim et al., 2011). Moreover, PEG is biocompatible and resistant to both protein
adsorption and cell adhesion, resulting in prolonged circulation times (Halperin, 1999).
Toxicity of methoxy PEG-b-PCL PMs loaded with indomethacin (an anti-inflammation
agent) and paclitaxel (an anti-cancer agent) were investigated in the previous study. After
7 days of intraperitoneal application of the median lethal dose of the drug-loaded PMs
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(which  was  much  higher  than  practical  effective  dose),  no  histological  changes  were
observed in heart, lung, liver or kidney using electron microscopy (Kim et al., 2003). A
toxicity study of PEG-PCL-PDEA PMs demonstrated that this type of PM is non-toxic up
to a dose of 0.5 mg/mL (Liu et al., 2010).
2.1.3 Lipid nanocapsules (LNCs)
LNCs  are  composed  of  1):  an  oily  core  made  of  medium  chain  triglycerides  (such  as
Labrafac® WL 1349); and 2): a hydrophilic and lipophilic non-ionic surfactant corona
composed of hydrophilic PEGs (e.g., Solutol® HS-15) and lipophilic lecithin (e.g.,
Lipoïd® S75–3) (Huynh et al., 2009). LNCs are biodegradable and are stable for six
months to one year in suspension (Hureaux et al., 2009; Huynh et al., 2009). Drug-loaded
LNCs can release their cargo continuously over several days (Lamprecht et al., 2002). By
varying the core component, concentration or viscosity of the lipid matrix, the drug release
kinetics can be modulated; however, the type of the surfactant only slightly affects drug
release, and the concentration of the surfactant does not affect drug release (Abdel-
Mottaleb et al., 2010; Jager et al., 2009; Maupas et al., 2011). These characteristics of
LNCs make them potential nanocarriers for inner ear drug delivery. Lipophilic agents and
hydrophilic DNA molecules can be encapsulated in the lipid core of LNCs (Béduneau et
al., 2008; Vonarbourg et al., 2009). The size of the LNC is determined by the
concentration of the surfactant in the corona, which affects surface tension; lower
concentrations  result  in  larger  LNCs  and  vice  versa.  The  type  of  surfactant  also  slightly
affects LNC size (Maupas et al., 2011).
PEGylated LNCs (i.e., coated with PEG) with PEG-660 can be rapidly cleared (with a 21-
min half-life) following intravenous injection (Ballot et al., 2006; Lamprecht et al., 2002).
However, LNCs PEGylated with PEG-1500, PEG-2000 or PEG-5000 exhibit a prolonged
blood circulation period in vivo (Béduneau et al., 2007; Béduneau et al., 2006; Hoarau et
al., 2004) (Fig. 4). PEGylation increases the stability of the LNCs (Ballot et al., 2006).
2.1.4 Peptide-functionalized nanocarriers
Peptide-functionalized nanocarriers were used for specific cell targeting or for enhancing
cellular internalization. TrkB antibody-conjugated PEG-b-PCL PMs exhibited CN-
specific binding, and OX26 antibody-conjugated LNCs exhibited increased blood brain
barrier permeation compared with controls following systemic application (Béduneau et
al., 2008; Roy et al., 2010). In the present study, the TAT peptide was used to enhance the
permeation of PMs across the RWM, and the Tet1 peptide was chosen to induce targeted
delivery of PMs. The biochemical properties of these two peptides are described below.
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2.1.4.1 TAT peptide
The TAT peptide has the sequence RKKRRQRRR and belongs to the cell-penetrating
peptide (CPP) family (Ruben et al., 1989). It has a strong positive charge with arginine-
and lysine-rich portions. The TAT peptide penetrates cell membranes by creating a hole in
the lipid membrane in an energy independent manner (Herce et al., 2007). The TAT
peptide has been used to carry variable cargos in cells, including peptides, proteins, genes,
and imaging agents (Baoum et al., 2009; Torchilin, 2007). The internalization rate of
TAT-labeled nanocarriers can be enhanced up to 100 fold when compared to unlabeled
nanocarriers (Torchilin, 2007). PMs functionalized with TAT peptide were shown
internalize into cells more efficiently compared with controls without affecting cell
functions (Christian et al., 2007). TAT peptide-labeled nanocarriers can cross a human
epithelial monolayer (Caco-2) through a transcellular pathway (Koch et al., 2005;
Lindgren et al., 2004). In contrast, it was reported that a TAT-GFP protein conjugate did
not pass through an intact endothelial cell monolayer with tight junctions (bEnd.3); it did,
however, cross an impaired monolayer (Simon et al., 2010a; Simon et al., 2010b).
2.1.4.2 Tet1 peptide
The sequence of the Tet1 peptide is ‘HLNILSTLWKYR’ and exhibits strong binding to
differentiated PC12 cells, primary motor neurons, and dorsal root ganglion cells via GT1b
receptors (Liu et al., 2005). Studies of GT1b receptors in the cochlea are rare. Two studies
reported that GT1b receptors are expressed in the cochlea (Maguchi et al., 1991; Santi et
al., 1994). This receptor was also reported to be expressed on peripheral nerve axolemma
(Sheikh et al., 1999). Tet1-conjugated non-viral vectors were also found to specifically
bind to neurons (Kwon et al., 2010; Park et al., 2007).
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2.2 Investigations of nanocarriers in inner ear
Nanocarriers loaded with drug, tracers and genes have been examined in the inner ear.
PEG-b-PCL PMs, the LNCs and silica nanocarriers loaded with fluorophores can pass
through the RWM and the oval window and are detected in the cochlea and the vestibulum
(Praetorius et al., 2007; Zou et al., 2008). PEG-PLA and PLGA nanocarriers can deliver
drugs to the inner ear via either local RWM or systemic application (Horie et al., 2011;
Horie et al., 2010). Contrast agents, such as gadolinium- tetraazacyclododecanetetraacetic
acid (Gd-DOTA) and superparamagnetic iron oxide nanoparticles (SPIONs), encapsulated
in liposomes, polymers and copolymers were visualized in the inner ear using magnetic
resonance imaging (MRI), light microscopy and electrical microscopy. The penetration of
the  nanocarriers  was  enhanced  through  the  use  of  an  external  magnetic  field  (Ge  et  al.,
2007; Kopke et al., 2006; Thaler et al., 2011; Zou et al., 2010b; Zou et al., 2011; Zou et
al., 2010c). Liposome and PEI polymers were reported to induce gene expression in the
inner ear (Jero et al., 2001; Tan et al., 2008). Peptide-functionalized PMs were shown to
be capable of targeting specific inner ear cell populations. For example, nerve growth
factor-derived peptide-functionalized PEG-b-PCL PMs can specifically target the CN and
SGCs (Roy et  al.,  2010).  In  the  present  study,  the  ability  of  Tet1-functionalized  PEG-b-
PCL  PMs  to  specifically  target  the  CN  and  of  the  TAT  peptide  to  promote  PEG-b-PCL
PM passage through the RWM were investigated.
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2.3 Delivery methods to the inner ear
Therapeutic agents for the treatment of inner ear diseases are being rapidly developed,
although the delivery method can have a significant impact on the therapeutic effect. It is
therefore necessary to choose an appropriate delivery method. There are two major local
inner ear therapeutic agent delivery methods (Fig. 2): intact RWM delivery and
intracochlear delivery (Bowe et al., 2010; Staecker et al., 2011; Swan et al., 2008). PLGA
nanocarriers delivered via systemic injection through the intact RWM or intracochlearly
were compared by Tamura et al. The results indicated that intracochlear delivery was the
most efficient in terms of delivering the nanocarriers to the cochlea, intact RWM delivery
was moderately efficient and systemic delivery exhibited the lowest efficiency (Tamura et
al., 2005). The systemic delivery of viral vectors resulted in no cochlear gene delivery
(Stöver et al., 2000). The low delivery efficiency and the significant side effects make
systemic administration an unideal method for treating inner ear diseases (Hoarau et al.,
2004; Robey et al., 2010). Local drug delivery is now extensively used for the treatment
and diagnosis of inner ear diseases in the clinic (Pyykkö et al., 2010; Robey et al., 2010).
Targeted drug delivery to the inner ear can be facilitated by choosing the optimal
approach. For instance, intracochlear delivery via the scala media or the ST is the most
efficient method for delivering gene vectors to Corti’s organ (Konishi et al., 2008;
Staecker et al., 2011). Alternatively, topical RWM delivery and transtympanic injection
are suitable for delivering substances to the perilymph of the inner ear (Zou et al., 2003b).
When substances cannot easily pass through the RWM, intracochlear delivery can be
considered (Konishi et al., 2008; Lalwani et al., 1997; Luebke et al., 2001).
Fig. 2 Drug delivery methods to the inner ear
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2.3.1 Topical RWM surface delivery and transtympanic injection
2.3.1.1 The RWM and the oval window
There are two openings between the middle and inner ear: the RWM and the oval window.
The RWM separates the ST of the inner ear from the middle ear. The oval window
separates the vestibulum from the middle ear.
The RWM consists of three layers in rats: an outer epithelial layer (a single layer of cells
facing the middle ear cavity); a connective tissue core; and an inner endothelial layer. The
outer epithelial layer has tight junctions on the middle ear side and a continuous basement
membrane beneath. The tight junction and the basement membrane protect the inner ear
from hazardous substances and bacteria, but at the same time they prevent therapeutics
from passing through RWM. The connective tissue core contains fibroblasts, collagen,
elastic fibers, blood and lymph vessels, and ‘gland-like’ structures at the RWM rim. The
collagen fibers are loosely arranged, and the ‘gland-like’ structures have openings on the
middle ear mucosal surface from which they secrete mucous materials into middle ear
(Goycoolea et al., 1997). The inner endothelial layer has large extracellular spaces,
allowing direct contact between the connective tissue core and the perilymph (Engmer et
al., 2008; Goycoolea et al., 1997). The thickness of the RWM is variable depending on the
species studied. This thickness is 6-10 µm in mice (Kitamura et al., 2002), 15 µm in rat
(Hellstrom et al., 1989), 10-14 µm in chinchilla (Goycoolea et al., 1997), 10 µm in guinea
pig (Saber et al., 2009), and 70 µm in human (Carpenter et al., 1989). Humans have the
thickest RWM, which is thicker at the rim than at the central region of the RWM.
The oval window is the barrier between the perilymph in the vestibulum and the middle
ear cavity. A histological study in rats demonstrated that the annular ligament across the
stapedio-vestibular joint is a porous structure composed of fibrillin, 36-kDa microfibril-
associated glycoprotein (MAGP-36), and hyaluronic acid (Ohashi et al., 2006; Ohashi et
al., 2008). The distance from the oval window to the saccule is 1.66 mm in humans, and
the distance to the utricle is 2.25 mm (Takahashi et al., 1992). In vivo MRI studies of
guinea pigs, rats, and humans indicate that the oval window is more permeable to
gadolinium than the RWM (Zou et al., 2005; 2010a). Selective vestibular delivery via the
oval window pathway was demonstrated by a recent MRI study (Zou et al., 2011b).
2.3.1.2 Permeability of the RWM
RWM permeability to proteins, drugs, biochemical compounds, viral vectors and
nanocarriers has been investigated. Following RWM surface application of antioxidants,
trimethylphenylammonium and glucocorticoids, a concentration gradient was observed
along the basal turn to the apex of the ST (Laurell et al., 2002; Mynatt et al., 2006; Plontke
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et al., 2008). The concentration gradient was thought to be the result of a balance between
the clearance and flow rates of the perilymph, but the concentration gradient decreased
with time (Salt et al., 2001; Aarnisalo et al., 2006; Plontke et al., 2008).
Permeability across the RWM is influenced by several factors, including the thickness of
the membrane and the size, configuration, concentration, liposolubility, and electrical
charge of the delivered substance (Goycoolea et al., 1997). The permeability of the guinea
pig RWM to bacteria endotoxins, dexamethasone, thiourea, methionine and
trimethylphenylammonium has been investigated, and the observed concentrations in the
basal turn perilymph were 0.01%, 0.01-6%, 1.4-2.4%, 1-2% and 16.5% of the original
concentrations, respectively (Laurell et al., 2002; Lundman et al., 1992; Mynatt et al.,
2006; Salt et al., 2001). In vivo and in vitro studies suggest that different viral vectors can
pass through the RWM and can be detected in the perilymph in a time-dependent manner,
except for associated adenoviruses (AAVs) (Aarnisalo et al., 2006; Jero et al., 2001;
Stöver et al., 2001). Nanocarriers, such as liposomes, polymers and polymer-encapsulated
SPIONs  were  shown  to  cross  the  RWM  (Jero  et  al.,  2001;  Zou  et  al.,  2008;  Zou  et  al.,
2010c). However, the penetration efficacy of nanocarriers is not as high as that of the viral
vectors. The chosen delivery method also influences the penetration of substances through
the RWM. For example, brain-derived neurotrophic factor (BDNF) administered by a
single transtympanic injection or sustained RWM application in rats resulted in 0.0001%
and 0.002% of the original concentration in the perilymph after 3 days, respectively (Endo
et al., 2005).
Several efforts have been made to improve the permeability of the RWM. For example,
disruption of the RWM epithelial layer was attempted with silver nitrate, trichloracetic
acid and phenol, but these methods did not achieve satisfactory results (Aarnisalo et al.,
2006; Suzuki et al., 2003). Partial digestion of the RWM using a collagenase solution
increased the RWM permeability to recombinant adeno-associated virus (rAAV) vectors,
resulted in elevated rAAV delivery and enhanced transfection efficacy (Wang et a., 2011).
Cell-penetrating peptides were also used to improve the passage of nanocarriers through
model membranes (Lindgren et al., 2004; Torchilin, 2007).
2.3.2 Intracochlear delivery
When a substance cannot penetrate the intact RWM or penetrates it poorly, intracochlear
delivery can be considered (Bowe et al., 2010). Intracochlear delivery can substantially
improve the therapeutic effect of the delivered cargo. Nanocarriers and viral vectors pass
poorly through the RWM but are efficiently delivered to inner ear cells when administered
via cochleostomy (Jero et al., 2001; Tamura et al., 2005). At present, intracochlear
delivery is the most efficient method for gene delivery to the inner ear (Konishi et al.,
2008; Staecker et al., 2011). Although hydrogel-administered BDNF to the topical RWM
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surface with sustained release was reported to partially protect SGCs from degeneration,
intracochlear application of BDNF resulted in full preservation of the SGCs (Agterberg et
al., 2009; Endo et al., 2005). During cochlear implantation, protective therapeutic agents,
such as neurotrophins and dexamethasone, can also be administered with the electrode
array (Paasche et al., 2006; Shepherd et al., 2002). However, intracochlear application of a
given substance is not an optimal method because it has the potential to induce
inflammation (Jero et al., 2001).
2.3.3 Communication pathways between perilymph and inner ear cells
In vivo MRI studies on small animals, including guinea pigs, rats, and mice, demonstrated
novel routes of gadolinium through the modiolus and lateral wall (Zou et al., 2005; 2009;
2010c; 2011b). Increased evidence for this novel communication route was obtained via
combined scanning electron microscopy and light microscopy in the human cochlea,
demonstrating  that  the  modiolar  wall  of  the  SV  and  ST  in  the  first  and  second  turn  is
porous, forming a perilymphatic communication route to the peri-vascular and peri-neural
spaces in the modiolus. A "peri-modiolar lymph" or fluid space can be identified in the
modiolar periphery (Rask-Andersen et al., 2006). Generally, there are four perfusion
pathways of substances into the inner ear (Fig. 3). The first is along the scala in the
perilymph (Salt et al., 2001). The second pathway is from the perilymph to the modiolus
through openings on the modiolar wall of the ST and SV; this short-cut may also be taken
advantage  of  therapeutically  given  that  PMs  migrate  to  the  SGCs  from  the  ST  (Rask-
Andersen et al., 2006; Zou et al., 2003b; Zou et al., 2009; Zou et al., 2010c; Zou et al.,
2011b).  Third,  perfusion  can  occur  from  the  ST  to  the  SV  via  either  the  SL  or  the
modiolus (Salt et al., 2005; Zou et al., 2003b ; Zou et al., 2005; Zou et al., 2009; Zou et
al., 2010c; Zou et al., 2011b); when substances enter the perilymph of the ST through the
RWM  or  intracochlearly,  they  perfuse  through  fibrocytes  of  the  SL  via  openings  in  the
mesothelial sheet facing the perilymph (Laurell et al., 2002; Rask-Andersen et al., 2006;
Salt et al., 1991). A fourth pathway is through Corti’s organ, which has a loose structure,
and drugs applied to the perilymph of the ST can access nearly all cochlear cell
populations and the nerve fibers of the peripheral processes of the SGCs (Ulfendahl et al.,
2000).  Lastly,  perfusion  can  occur  between the  basal  SV and  the  vestibulum (Salt  et  al.,
2005).
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Fig. 3 Arrows show the opening position in ST and SV.
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3. AIMS OF THE PRESENT RESEARCH
The purposes of the present study were 1) to evaluate the efficacy of PM delivery into the
inner ear via different methods; 2) to facilitate the outcome of the cell-penetrating peptide-
TAT; 3) to determine the in vivo targetability of Tet1 peptide-functionalized PMs; and 4)
to examine the distribution and biocompatibility of LNCs in the rat inner ear.
This study had the following specific aims:
I. To improve visualization of PEG-b-PCL polymersomes by quenching
autofluorescence. (Study I).
II. To compare the distribution of PEG-b-PCL polymersomes administered via
different methods in rat inner ear cells (Study II).
III. To evaluate the permeability of the RWM to TAT-PEG-b-PCL
polymersomes and the axonal targeting of Tet1-PEG-b-PCL polymersomes
in the rat inner ear. (Study III)
IV. To evaluate the distribution and toxicity of lipid nanocapsules (LNCs) in the
rat inner ear following topical RWM application. (Study IV and V)
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4. METHODS AND MATERIALS
4.1 Subjects
4.1.1 Polymersomes and lipid nanocapsules
PMs were provided by school of Biological Sciences, University of Southampton. LNCs
were provided by Universite´ d’Angers-INSERM U646 Inge´ nierie de la Vectorisation
Particulaire.
4.1.1.1 Polymersomes
Brifly, NH2-PEG5.8K-b-PCL19K (60 mgs, Polymer Source Inc., Canada) was dissolved
in 2 mL dimethylformamide (DMF, Sigma-Aldrich, UK). 4-nitrophenyl-iodoacetate (10
mg, Sigma-Aldrich, UK) was added and the reaction mixture stirred for 4 hours. Diethyl
ether (50 mL, Polymer Source Inc., Canada) was added and the solution left overnight, the
resulting precipitate was filtered and washed with diethyl ether to give iodoacetate-
PEG5.8K-b-PCL19K functionalized polymer (45 mg, 75% yield). 15 mg of the solid was
dissolved into DMF (1 mL) and then peptide (1 mg) was added. The peptide sequences
(Protein Peptide research Ltd, UK) used were Tet1 (NH2-HLNILSTLWKYRC-COOH), a
scrambled Tet1 sequence (ScrTet1) (NH2-LHNYTWLSLRKIC-COOH), TAT (NH2-
CYGRKKRRQRRRA-COOH) and a scrambled Tat sequence (ScrTAT) (NH2-
CRYRKRKGRARQR-COOH).
The carboxy cyanine dye 1,1’-Dioctadecyl-3,3,3’,3’-tetramethyl-indocarbocyanine
perchlorate (DiI, Invitrogen, UK) was dissolved in DMF at a concentration of 0.1 mg/mL.
Tet1-PEG5.8K-b-PCL19K (6.0 mg) was added to the DiI/DMF solution (0.4 mL). The
polymer solution was then added dropwise (~1 drop every 8 seconds) to rapidly stirring
phosphate  buffered  saline  (PBS,  Oxoid,  UK)  (1.60  mL).  The  sample  was  then  dialyzed.
Control PMs with the scrambled ScrTet1 peptide (ScrTet1-PMs) and unlabelled PMs were
made using ScrTet1/TAT-PEG5.8K-b-PCL19K and iodoacetate-PEG5.8K-b-PCL19K
respectively. Diameter of the Tet1-PMs analyzed by DLS was 105.0 (+/-) 20.0 nm. Both
of ScrTet1-PMs and unlabelled PMs had typical hydrodynamic diameters similar to the
Tet1-PMs. The preparation of TAT-PMs was identical,  however the amounts of polymer
used were TAT-PEG5.8K-b-PCL19K (1 mg) and PEG5K-b-PCL5K (5 mg). For the
preparation  of  control  samples  of  ScrTAT-PMs  and  unlabelled  PMs  the  Tat  labelled
polymer was replaced with ScrTAT-PEG5.8K-b-PCL5K and iodoacetate-PEG5.8K-b-
PCL19K respectively. The typical hydrodynamic diameter of the TAT-PMs and the
control  samples  were  62.6  (+/-)  9.2  nm.  The  zeta  potential  was  measured  on  a  Malvern
Nanosizer. There was no difference in the zeta potential measurements for the Tet-PMs
and ScrTet1-PMs, as was the case for the TAT-PMs and ScrTAT-PMs. The typical
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measurements for the Tet1-PMs, the Tat-PMs and the unlabelled PMs were -0.764, -1.63
and  -0.578  mV  respectively.  Before  use  in  in  vivo  experiments  the  PMs  were  sterile
filtered through a 0.2 µm cellulose acetate syringe filter.
4.1.1.2 Lipid nanocapsules
Emulsion of Labrafac® WL 1349 (kindly provided by Gattefossé SA. Saint-Priest,
France), an oil made of capric and caprylic acid triglycerides (average molecular weight of
512); Lipoïd® S75-3 (gift from Lipoïd Gmbh, Ludwigshafen, Germany), a soybean
lecithin made of 69% phosphatidylcholine and other phospholipids; Solutol® HS 15 (gift
from BASF, Ludwigshafen, Germany), another surfactant; polyethylene glycol 660
hydroxystearate (C18E15); and free polyethylene glycol 660 at room temperature (oil in
water).  The  optimal  amounts  of  ingredients  for  preparation  of  50  nm  of  LNCs  were:
Labrafac® (1.028 g), Lipoïd® (0.075g), Solutol® (0.846 g), NaCl (0.089 g) and pure water
(2.962 g). After progressive heating at a rate of 4 ºC/min under magnetic stirring, a short
interval of transparency at temperatures close to 70 ºC, and the inverted phase (water
droplets in oil) was obtained at 85 ºC. Then, three cycles of cooling and heating were
applied between 85 ºC and 60 ºC at the same rate of 4 ºC/min (close to the phase inversion
zone). Finally, rapid dilution in cold water at a temperature close to 0 ºC produced a
suspension of nanocapsules.
For pegylation, the LNCs were incubated for 90 min with DSPE-PEG-amino at 60 ºC. The
suspension was vortexed every 15 min and then quenched in an ice bath for 1 min. The
final DSPE-PEG concentration corresponded to 6 mol % of total surface molecules (i.e.,
Solutol and Lipoïd). For fluorescence labeling, 2 mg of Fluorescein-5-isothiocyanate
(FITC,  Fluorescéine  IsoThioCyanate,  France)  was  added  to  2.95  mL  of  the  LNC
suspension, and the pH was increased to 10 by adding a few drops of 0.1M Na3PO4
solution.  The  sample  was  stirred  at  35ºC for  45  min.  The  sample  was  cooled  in  order  to
stop the reaction, and size exclusion chromatography utilizing a Sephadex G-15 column
was performed to separate free FITC from labeled LNCs. Fractions corresponding to the
FITC-labeled LNCs were analyzed by dynamic light scattering. The hydrodynamic
diameter  of  52  ±  5  nm  and  a  zeta  potential  of  -35  ±  7  mV  (for  non-labeled  LNCs,  we
obtained diameter of 48.9 nm, zeta potential of 5.0 ± 0.5 mV and concentration of 123
mg/ml). For Rhodamine B (ChemExper Inc., Belgium) labeling, FITC was replaced by 2
mg Rhodamine B.
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Fig. 4 Structure of polymersomes (A) and lipid nanocapsules (B). PEG: poly(ethylene glycol); PCL: poly(?-
caprolactone); DiI: 1,1’-Dioctadecyl-3,3,3’,3’-tetramethyl-indocarbocyanine perchlorate.
4.1.2 Animals
Topical RWM surface delivery was assessed for TAT-PMs, ScrTAT-PMs and unlabeled
PMs by placing gelatin sponge pledgets saturated in solutions of these nanocarriers on the
RWM. The left cochlea was treated with TAT-PMs and the right cochlea was treated with
ScrTAT-PMs. Unlabeled PMs were applied bilaterally to the RWM. Three days following
the beginning of delivery, the animals were sacrificed and the cochleae were harvested and
whole-mounted for confocal microscopy (Table 1).
One group of animals received bilateral transtympanic injections of Tet1-PMs, ScrTet1-
PMs  or  unlabeled  PMs  to  the  middle  ear  cavity.  Three  days  following  injection,  the
cochleae were harvested. Four cochleae from each treatment group were whole-mounted.
The other four cochleae were decalcified with 10% ethylenediaminetetraacetic acid
(EDTA, Merck) and processed for cryosectioning (Table 1).
Another group of rats were treated with Tet1-PMs, ScrTet1-PMs or unlabeled PMs via left
bulla cochleostomy unilaterally. Three days following administration, the cochleae were
harvested. Two cochleae were whole-mounted and three were decalcified with 10%
EDTA and processed for cryosectioning (Table 1).
Six rats were used to examine LNC distribution. Five LNC-treated rats and five sodium
chloride (NaCl)-treated rats were used to test hearing thresholds. Ten untreated rats were
used as controls (Table 1).
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Table 1 List of cochleae numbers used in the present study
4.1.3 Ethical aspects
Sprague-Dawley (SD) rats supplied by the experimental animal unit, University of
Tampere were used in the study in accordance with the local ethics committee of
University of Tampere standards (permission no: 985/2003).
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4.2 Methods
4.2.1 Methods to administer nanocarriers to inner ear
Animals were anesthetized by 0.8 mg/kg medetomidine hydrochloride (Domitor, Orion,
Finland) and 80 mg/kg ketamine hydrochloride (Ketalar, Pfizer, UK). The operation was
performed under sterile conditions: surgical towels were autoclaved and operating
instruments were sterilized by a bead sterilizer (STERI 250, Switzerland). The animals
were placed on a thermo-regulated heated pad covered with surgical towel in a rightward
lateral position.
For intact RWM application by gelatin sponge, a small piece of gelatin sponge
(Gelfoam®) pledget soaked in nanocarriers (around 8 mm3 soaking with 10µl nanocarriers
solution) was placed near the round window niche and covered on the RWM.
For transtympanic injection to middle ear, 40µl of nanocarrier solution was injected into
the middle ear cavity using a 27 gauge needle.
For sustained application of nanocarriers to the RWM using osmotic pumps (TAT-PMs,
ScrTAT-PMs and the unlabeled PMs in Study III), post-auricular pathway was chosen. A
hole was drilled on the bulla with a 2 mm diameter burr. After identifying the stapes
artery, the RWM was identified above the artery, a small piece of gelatin sponge
(Gelfoam®) pledget, around 8 mm3,  soaked  in  nanocarrier  solutions  was  placed  on  the
RWM. The micro-osmotic pump (ALZET®, 1003D) was filled with 100 µl PM solutions
and connected to a catheter (PE60, Becton Dickinson and Company) prefilled with the
same solution (Fig. 5). The catheter tip was placed onto the gelatin sponge, the catheter
was fixed on the bulla with Phosphate Cement (Heraeus Kulzer GmbH, Germany), and the
osmotic pump was implanted subcutaneously in the neck.
                      Fig. 5 Osmotic pump used in the sustained delivery.
For PMs applied to ST by osmotic pumps through cochleostomy, after visualizing the
stapes  artery  as  previously  mentioned,  the  ST  was  identified  below  the  artery.  A  small
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hole was drilled on the bony labyrinth with a 1 mm diameter burr. The micro-osmotic
pump (1003D, Alzet, Canada) was filled with 100 µl nanocarrier solutions and connected
to a catheter (PE60, Becton Dickinson and Company) prefilled with the same solution
(Fig. 5). The catheter tip was inserted into the hole and the surroundings sealed by a small
piece of muscle. A drop of tissue adhesive (Histoacryl®,  B.  BRAUN,  Germany)  was
applied to the muscle to fix the catheter.  Finally the catheter was fixed on the bulla with
Phosphate Cement (Heraeus Kulzer GmbH, Germany), and the osmotic pump was
implanted in the neck.
 After operation, Rimadyl (1.0 mg/kg, Pfizer,UK) was injected i.p to relieve pain. Baytril
(10 mg/kg, Orion, Germany) was injected i.p. once a day to prevent potential middle ear
infection. Antisendan (Atipamezole hydrochloride, Orion pharma, Finland) (2 mg/kg) was
injected i.p. after the operation to accelerate recovery from anaesthesia of the animals.
4.2.2 Specimen preparation
The rats were anaesthetized using the previously described method. The bullae were fixed
by cardiac perfusion with 4% Paraformaldehyde (PFA) (Merck, Germany) [0.01 M PBS
containing 0.6% (v/v) heparin, pH 7.4 to remove the blood before fixation]. No
inflammation was found in the middle ear cavity of all animals. The isolated cochleae
were rinsed with tap water for 1 minute to remove free nanocarriers on surface, and the
samples further stored in the 4% PFA solution for 2 hours.
For whole mounted samples, after washing with PBS, the basal turn, middle turn, and
apex (include Corti’s organ, spiral ligament, and modiolus) of the cochlea, the round
window membrane, the saccule, the ultricle and the ampullae of vestibular were isolated.
The tectorial membrane was removed under a stereo-microscope.
Cochleae were decalcified with 10% EDTA (ph 7.2) for 3 weeks. For paraffin sections, a
standard paraffin embedding procedure was used and the samples were sectioned at 5 µm
thickness (Study V). For cryosections, cochleae were incubated in 30% sucrose overnight
at  4  ºC,  embedded  in  O.C.T.  compound  (Tissue  Tek®), sectioned with cryostat (Leica
CM3050S, Germany) at 30 µm thickness (Study III).
4.2.3 Quenching of autofluorescence (Study I)
To investigate autofluorescence in inner ear cell populations, after stained with 4',6-
diamidino-2-phenylindole (DAPI) (10 µg/ml, Sigma-Aldrich, USA) for 10 min at room
temperature in the dark, the isolated cochlea tissue (Corti’s organ, spiral ligament,
modiolus, and the ampullae of vestibular) was washed with PBS, placed on 8-well slides
(Cel-Line/Thermo scientific, USA) and mounted with Fluoromount (Sigma-Aldrich,
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USA) for confocal microscopy.
To detect the quenching effect of CuSO4 treatment on autofluorescence of cochlea tissue
and specific labeling of the inner ear cell populations, isolated cochlea tissue were stained
with FITC-conjugated phalloidin (50µg/ml, Sigma Aldrich, USA) and antibody against
Neurofilament-200  (the  secondary  antibody  was  conjugated  with  FITC).  After  stained
with DAPI (10 µg/ml) for 10 min at room temperature in the dark, the isolated cochlea
tissue was treated with 1 mM CuSO4 in 0.01 M ammonium acetate buffer (pH 5.0) for 90
min.  After  washing  with  PBS,  the  specimens  were  placed  on  8-well  slides  and  mounted
with Fluoromount for confocal microscopy.
DiI encapsulated PMs were prepared with 1 mM CuSO4 in 0.01 M ammonium acetate
buffer (pH 5.0). The fluorescence intensity of the PMs was measured at 0 and 90 min by a
spectrofluorometer (Photon Technology International, UK, serial number: 2406) equipped
with FeliX32 operating software. For the untreated control, the PMs were prepared with
0.1  M  PBS  and  measured  at  the  same  time  points  as  the  CuSO4-treated samples. The
fluorescence signal intensities of the CuSO4-treated and untreated samples were corrected
with the CuSO4 and PBS references, respectively. Five trials were repeated.
4.2.4 Immunohistochemistry
4.2.4.1 Antibodies
To investigate the quenching effect of CuSO4 treatment on specific labelling, rabbit anti-
NF-200 polyclonal antibody (1:200 in 0.1% BSA, Sigma Aldrich, USA) was used (Study
I). In the PCL-b-PEG polymersome distribution study, NF-200 (1:200 in 0.1% BSA),
rabbit anti-S-100 polyclonal antibody (1:200 in 0.1% BSA, Abcam, USA), and rabbit anti-
Periphrin polyclonal antibody (1:100 in 0.1% BSA, Millipore, CA) were applied (Study
III). In the LNC toxicity study, NF-200 antibody (1:200), S-100 antibody (1:400), purified
mouse anti-CtBP2 monoclonal antibody (1:200, BD Transcription laboratorios, USA), and
mouse monoclonal antibody to synaptophysin (1: 200, Sigma-Aldrich, USA) were used
(Study V).
Secondary antibodies include FITC-labeled goat anti-rabbit IgG (1:200, Sigma-Aldrich,
USA), FITC-labeled goat anti-mouse IgG (1:200, Sigma-Aldrich, USA), Alexa Fluor-568
labelled goat anti rabbit IgG (1:400, Invitrogen, USA) or TRITC labelled goat anti mouse
IgG (1:400, Invitrogen, USA) were used depending on the host of primary antibodies.
4.2.4.2 Immunostaining procedure
The paraffin sections were deparaffined. The cryosections were washed with PBS for 5
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min  x3.  Then  the  samples  were  incubated  with  goat  serum (1:20  with  0.1% BSA) for  1
hour at room temperature, incubated with primary antibodies as previously described over
night at 4ºC, washed with PBS-T, incubated with secondary antibodies for 1 hour at room
temperature, washed with PBS-T, stained with 10µg/ml DAPI for 10 minutes, and
mounted with Fluoromount for confocal microscopy observation.
4.2.5 Apoptotic analysis
The specimens were deparaffinized, treated with 0.1% Triton-X100, incubated with 0.1%
trypsin at 37ºC, irradiated with 0.1M citrate buffer (PH 6.0) at 350W microwave
irradiation, and washed with PBS. For positive control, tissue was incubated with 0.2 µg
/ml  Proteinase  K  in  50  mM  Tris  buffer  (pH  7.5).  Terminal  deoxynucleotidyl  transferase
dUTP nick end labeling (TUNEL; Roche Diagnostic GmbH, Germany) mixture
(20µlEnzyme solution in 180µl lable solution) was applied on slides (50µl label solution
on negtive control slides) for 60 minutes at 37ºC, washed with PBS, and whole mounted
with Gel Mount TM Aqueous Mounting Medium (Sigma-Aldrich, USA) for confocal
microscopy.
4.2.6 Confocal microscopy
The samples were observed using an Olympus microscope (Eclipse Ti) installed with
ANDOR IQ software. The excitation lasers were 405 nm (blue excitation), 488 nm (green
excitation), and 561 nm (red excitation) with Lambda 10-2 (Sutter instrument co.) as the
excitation source. The corresponding emission filters were 525/50 (FITC), 607/45 (TRITC
and Alexa 568) and 447/60 (DAPI). For 3D scanning, the inter slice thickness was 0.5 µm.
4.2.7 Auditory brainstem response measurement (Study V)
BioSig32 (Tucker Davis Technologies, USA) was used for ABR threshold recording .A
click duration of 50 µs and a repetition rate of 21.1/s were used for stimulation. Responses
from 500 sweeps were averaged with a gain of 20 at each intensity level using a filter of
0.1–3 kHz. Thresholds were judged by visible repeatable minimum response.
The latency interval between peakI and peakII (IntervalpeakI-II) at 50dB were compared
among groups or different time points. The time points were as follows: before surgery, 2
h post-administration, 1 week post-administration (D7), 2 weeks post-administration
(D14), 3 weeks post-administration (D21), and 4 weeks post-administration (D28).
4.2.8 Analysis and statistics
Statistical analyses were performed using the SPSS 11.5 software package. For the
spectrofluorometer study, the fluorescence signal intensities and the remaining levels of
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DiI-encapsulated PMs in CuSO4-treated and untreated samples were compared using
Student’s t-tests at different time points. The fluorescence of PMs on confocal
microscopic images of the RWM, SL, and vestibulum (utricle and saccule) was measured
using ImageJ 1.42q software. The fluorescence intensity was determined using pixel gray
values ?1 following subtraction of the background noise. The fluorescence intensities of
the PMs delivered using the three methods were compared with the Kruskal-Wallis Test
using SPSS 11.5 software. Colocalization of the Tet1-PMs, ScrTet1-PMs and unlabeled
PMs with NF-200 immunostaining in confocal micrographs was analyzed using ImageJ
1.42q software. In the LNC toxicity study, ABR thresholds were compared at different
time points using one-way analysis of variance (ANOVA), and a Bonferroni test was used
for pairwise multiple comparisons of ABR measurements. An independent sample T-test
was used to comparison compare the number of ribbon synapses between the different
groups. A p-value of less than 0.05 was considered significant.
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5. RESULTS
5.1 Autofluorescence in rat inner ear (Study I)
5.1.1 Autofluorescence
In whole-mounted specimens, autofluorescent dots were observed in the subcuticular
cytoplasm of inner hair cells (IHCs). Clear autofluorescence dots were also detected in the
SGCs, strial marginal cells, SLFs, mesothelial cells of the ST below the basilar membrane,
and in the epithelial cells of Reissner’s membrane. A sparse distribution of
autofluorescence was observed in outer hair cells (OHCs). No autofluorescence was
observed in the supporting cells, including Deiters’ cells, Hensen or Claudius cells (Fig. 6
and Fig. 7).
5.1.2 Quenching of autofluorescence
Following 90 min of CuSO4 treatment,  no  autofluorescence  was  visible  in  any  of  the
specimens. Moreover, the specific labeling from FITC-conjugated phalloidin and NF-200
stained with a FITC-goat anti-rabbit IgG antibody were not visibly decreased following
CuSO4 treatment (Fig. 7 D-F).
Fluorospectrometer results indicated that 90 min of CuSO4 treatment does not reduce the
fluorescence intensity of DiI-tagged PMs (Table 2). The in vivo study demonstrated that
visualization of DiI-tagged PMs was not affected by a 90 min of CuSO4 treatment (Fig. 8
and Fig. 9).
Table 2 Fluorescence intensity of CuSO4 and PBS treated DiI tagged polymersomes
CuSO4 treatment (x104)
(Mean±SEM)
PBS treatment (x104)
(Mean±SEM)
Before 59.2±2.4 58.6±5.9
90 minutes treatment 44.5±5.5 44.5±1.8
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Fig. 6 Autofluorescence in inner hair cells, spiral ganglion cells, spiral ligament fibrocytes and strial
marginal cells. Red: autofluorescence in red channel; Green: autofluorescence in green channel; Blue: DAPI.
IHC: inner hair cell; SGC: spiral ganglion cell, SL: spiral ligament. Scale bar=10µm. (Figure 2 in Study I)
Fig. 7 Autofluorescence was detected in inner hair cells (arrows in A and F), outer hair cells (arrowheads in
A and F), spiral ganglion cells (arrows in B, E and J) and vestibule (C). Autofluorescence was diminished by
CuSO4 treatment for 90 min (F-J). Green: Phalloidin (A-C and F-H) and NF-200 immunostaining (D, E, I
and J); Red: autofluorescence; Blue: DAPI. IHC: inner hair cell; OHC: outer hair cell; SGC: spiral ganglion
cell. Scale bar=10µm.
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5.2 Polymersomes delivered via different methods (Study II)
Three methods were used to deliver PMs into the inner ear: topically on the RWM surface,
transtympanic injection and intracochlear delivery.
5.2.1 Cochlear distribution of the polymersomes
The RWM distribution of the PMs was examined in all animals, with significantly lower
fluorescence signals in the topical RWM group than in the other two groups (p < 0.01;
Table 3). PMs delivered via topical RWM and transtympanic injection were only detected
in the outer epithelial layer of the RWM, but they were detected in all three layers in the
cochleostomy group (Fig. 8 A1; Fig. 9 G and H).
In the SL, PMs were detected in all animals by analysis of whole-mount specimens (Fig. 8
D, I and N). In the stria vascularis, PMs were observed in the lumens of the capillaries in
the topical RWM group and in the pericytes of the capillaries in the cochleostomy group
(Fig. 8 C and M). PMs were observed in Hensen and Claudius cells of Corti’s organ in the
cochleostomy group (Fig. 9 E). PMs delivered via cochleostomy were also detected in the
spiral ganglion (Fig. 8 O and Fig. 9 F). PMs were detected in the mesothelial cells beneath
Corti’s organ in the transtympanic injection and cochleostomy groups (Fig. 8 G and L;
Fig. 9 E).
Table 3 Quantification of polymersome uptake in rat cochlea delivered via three methods
RWM (x104 pixels)
(Mean±SEM)
SL (x104 pixels)
(Mean±SEM)
Vestibulum (x104 pixels)
(Mean±SEM)
Topical RWM 12.7±1.4** 12.1±1.2 9.2±2.6*
Transtympanic injection 32.8±3.2 11.0±0.8 27.8±3.3
Cochleostomy 33.3±8.9 20.4±2.0## 23.1±2.8
**: p < 0.01 and *: p < 0.05 significantly lower than the other two delivery methods (Kruskal-Wallis Test)
##: significantly higher than the other two delivery methods, p < 0.01 (Kruskal-Wallis Test)
RWM: round window membrane; SL: spiral ligament.
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Fig. 8 Whole-mounted samples show unlabeled polymersomes administered via topical round window
membrane (A-E), transtympanic injection (F-G) and cochleostomy. Arrows in A2 indicate nuclei in the
connective tissue layer of the RWM. Arrows in C, H and M indicate the nuclei of the endothelial cells of the
strial capillaries. Asterisks in E, J and O indicate the nuclei of spiral ganglion neurons. Red: PMs. Blue:
DAPI.  RWM: round window membrane; StrV: strial vascularis; SL: spiral ligament. Scale bar = 10 µm.
(Figure 5 B in Study I; Figure 2 in Study II)
Fig. 9 Cryosections show unlabeled polymersomes delivered via cochleostomy and transtympanic injection.
Panels A and B show the unlabeled PMs surrounding a blood vessel in the SL (B is a magnified image of the
rectangular  area  in  A).  Panel  C  shows  the  unlabeled  PMs  in  type  III  and  type  IV  SLFs.  Panel  E  shows
unlabeled PMs in the CN within the spiral lamina canal, in mesothelial cells beneath Corti’s organ (arrow),
and in supporting cells in Corti’s organ (arrowhead). Panel F shows unlabeled PMs in the spiral ganglion.
Panels G and H show unlabeled PMs in the RWM (1: epithelial layer; 2: connective tissue layer; 3:
endothelial layer). Red: PMs; Blue: DAPI. RWM: round window membrane; SL: spiral ligament; ST: scala
tympani. Scale bar = 50 µm. (Figure 3 and Figure 4 in Study II)
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5.2.2 Vestibular distribution of the polymersomes
Measurements of the fluorescence signal from confocal images of whole-mounted
samples indicated that more PMs were delivered into the vestibulum via transtympanic
injection and cochleostomy than by topical RWM (p < 0.05; Table 3). The fluorescence
signals of the PMs delivered by transtympanic injection and cochleostomy were not
statistically  different  (p  >  0.05;  Table  3).  However,  cryosections  indicated  that  the  PMs
delivered by transtympanic injection were located in the endolymphatic and perilymphatic
spaces of the vestibulum (Fig. 10 A and B). In contrast, PMs delivered via cochleostomy
were present in the utricular branch of the vestibular nerve and in mesothelial cells of the
SCC facing the perilymph (Fig. 10 C and D).
Fig. 10 Cryosections indicate that polymersomes were present in vestibulum. Red: PMs; Blue: DAPI. Scale
bar=10 µm. (Figure 5 in Study II)
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5.3 Peptide-functionalized polymersomes
5.3.1 TAT-functionalized polymersomes (Study III)
Uptake  of  TAT-PMs  in  RWM  was  significantly  higher  than  that  of  ScrTAT-PMs  or
unlabeled PMs (p < 0.05). In the mesothelial cells beneath Corti’s organ, the uptake of
TAT-PMs was significantly higher than unlabeled PMs (p < 0.05) and tended to be higher
than that of ScrTAT-PMs (p = 0.065). In the SL, the uptake of TAT-PMs was significantly
higher than that of ScrTAT-PMs (p < 0.05) but not the unlabeled PMs (p = 0.074, Table 4
and Fig.  11).  TAT-PMs were observed in outer sulcus cells where the ScrTAT-PMs and
the unlabeled PMs were not presented. TAT-PMs were detected in SGSCs in one animal
(Fig. 11).
Table 4 Quantification of polymersome uptake in the rat cochlea after topical round
window membrane administration.
RWM (x104 pixels)
(Mean±SEM)
Mesothelial cells (x104 pixels)
(Mean±SEM)
SL (x104 pixels)
(Mean±SEM)
TAT-PMs 30.9±3.4 15.6±1.1 12.9±1.9
ScrTAT-PMs 11.0±0.7* 8.9±1.0 9.2±2.1
Unlabeled PMs 12.7±1.4* 9.2±1.2* 12.1±1.5*
*: p < 0.05 compared with TAT-PMs (Kruskal-Wallis test)
RWM: round window membrane; SL: spiral ligament
Fig. 11 Distribution pattern of TAT-PMs and ScrTAT-PMs in cochlear cells. Green in A, C, F and H: FITC-
conjugated phalloidin. OSC: outer sulcus cells; PMs: polymersomes; RWM: round window membrane;
SGC: spiral ganglion cell; SL: spiral ligament. Red: PMs. Blue: DAPI. Scale bar=10 µm. (Figure 3 in Study
III)
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5.3.2 Tet1-functionalized polymersomes (Study III)
5.3.2.1 Tet1-PMs administered by cochleostomy
Only the Tet1-PMs were detected in the tractus spiralis foraminosus (TSF) region (Fig. 12
and Fig.  13  A),  which  is  multiple  tiny  osseous  canals  that  allow axons  to  pass  from the
Rosenthal canal to the cochlea nerve in the modiolus. Tet1-PMs were colocalized with or
adjacent to NF-200 immunostaining (Fig. 13 B and F). However, the ScrTet1-PMs and the
unlabeled PMs were remote from NF-200 immunostaining (Fig. 13 C and D). All the three
types of PMs were internalized by SGSCs which was identified by co-localization with
S100 immunostaining (Fig. 14 C, F and I). None of the PMs were observed in the
neuronal soma of SGCs.
In addition, all the tested PMs were observed in the RWM, the mesothelial cells in the ST
and SV, the CN in the spiral lamina canal and in the modiolus, the spiral ganglion (SG) in
Rosenthal’s canal and the anterior and posterior spiral modiolar vein in modiolus. The
scrambled and the unlabeled PMs were occasionally observed in Hensen and Claudius
cells  (Fig.  8  E).  Tet1-PMs  were  observed  in  type  II,  III,  IV  and  V  SLFs.  ScrTet1-PMs
were detected in type I, II, III, IV and V SLFs. Unlabeled PMs were only detected in type
III and IV SLFs.
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Fig. 12 Illustration of the distribution of Tet1-PMs, ScrTet1-PMs and unlabeled polymersomes after delivery
using cochleostomy. In the CN within the spiral lamina canal, the CN in the tractus spiralis foraminosus
(TSF) region and the SL, the distribution patterns of the Tet functionalized and control PMs were different.
Arrowheads: the openings in ST that allowed the PMs to pass through (Rask-Andersen et al., 2006). White
arrows with dashed line: the possible routes of PM distribution in the inner ear. CN: cochlear nerve; RWM:
round window membrane; SL: spiral ligament; SGCs: spiral ganglion cells; TSF: tractus spiralis
foraminosus. (Figure 4 in Study III)
Fig. 13 Cryosections showing the distribution pattern of polymersomes with and without Tet1
functionalization in the rat cochlea following administration via cochleostomy. Tet1-PMs (A) and ScrTet1-
PMs (E) were detected in the SGCs and in nerve fibers in the tractus spiralis foraminosus (TSF) region. Only
Tet1-PMs were detected in the TSF region (arrows in A). Panels B-D show the co-localization of the PMs
with NF-200 (arrows in panel B). The co-localized points are indicated by black dots in panels F (arrows), G
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and H (analyzed by ImageJ software). Arrowheads in panel B point to SGCs. Red: PMs; Green: NF-200;
Blue:  DAPI.  Gray:  bright  field.  PMs:  polymersomes;  SGCs:  spiral  ganglion  cells.  Scale  bar  =  10  µm.
(Figure 6 in Study III)
Fig. 14 Distribution of polymersomes in the spiral ganglion cells after administration via cochleostomy. All
three types of the PMs administered by cochleostomy were located in SGSCs (arrows). PMs were not
detected in the neuronal soma of the spiral ganglion clees (*: nucleus of type I spiral ganglion cells). Red:
PMs;  Green:  NF-200  or  S100  immunostaining.  Blue:  DAPI.  PMs:  polymersomes.  Scale  bar  =  10  µm.
(Figure 7 in Study III)
5.3.2.2 Tet1-PMs administered by transtympanic injection (Study III)
Tet1-PMs, ScrTet1-PMs and unlabeled PMs were detected in RWM, SLFs, mesothelial
cells of the SV and ST, Reissner’s membrane and the vestibular system. However, no PMs
were observed in the SGCs or the CN (Fig. 15).
Fig. 15 Distribution pattern of Tet1- and ScrTet1-PMs in the inner ear. PMs: polymersomes; SGCs: spiral
ganglion cells; SL: spiral ligament; ST: scala tympani. Red: PMs. Blue: DAPI. Scale bar = 10 µm.
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5.4 Distribution and toxicity of lipid nanocapsules in the rat
inner ear
5.4.1 Distribution of lipid nanocapsules in the rat inner ear (Study IV)
Following a topical RWM surface delivery of 30 min, LNCs were observed in the
stapedial artery and in typeV SLFs (Fig. 16 A-E). Following an application of 1 hour,
LNCs were also detected in the StrV and spiral prominence (Fig. 17 A and B). Following
an application of 24 hours, intense accumulations of LNCs were observed in the RWM,
the mesothelial cells beneath Corti’s organ, the SL, the modiolus, and the stapedial artery
(Fig. 16 F-J). Following 1-hour and 24-hour treatments, the LNC signal was stronger
compared to the 30-min and 7-day applications (Fig. 17 C). In each of the groups, red
fluorescence was frequently apart from green fluorescence.
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Fig. 16 Lipid nanocapsule distribution pattern in the cochlea. Panels A-C are pictures from cryosections.
Panels E and J show that red and green fluorescence from the LNCs were separate in the stapedial artery
(arrows: Nile Red; arrowheads: FITC). Red and Green: Nile Red and FITC from LNCs; Blue: DAPI. LNCs:
lipid nanocapsules; RWM: round window membrane; SL: spiral ligament. Scale bar=10 µm. (Figure 2 C and
M; Figure 4 A in Study IV)
Fig.  17  Cryosections  show the  distribution  of  lipid  nanocapsules.  Panels  A and B show LNCs in  the  StrV
and the SP following a 1-hour application on the RWM. Panel C shows LNCs in the mesothelial cells
beneath Corti’s organ following a 7-day application. Green and Red: FITC and Nile Red from LNCs; Blue:
DAPI. LNCs: lipid nanocapsules; StrV: strial vascularis; SP: spiral prominence. Scale bar=10 µm. (Figure 6
D in Study IV)
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5.4.2 Toxicity study of lipid nanocapsules in the rat inner (Study V)
5.4.2.1 Hearing results
Immediately following LNC treatment (D0), ABR thresholds were increased in both the
LNC-treated group and the NaCl control (p < 0.05; Table 5). After seven days of treatment
(D7), ABR thresholds recovered to pre-treated level (p > 0.05). The ABR latency interval
between peaks I and II (IntervalpeakI-II) at 50dB was prolonged at D0 in both the NaCl
control and LNC-treated groups when compared to pre-treatment, even though only the
NaCl group was significantly different (p < 0.01; Table 6).
Table 5 Auditory brainstem response thresholds during test period (Mean±SEM)
Before D0 D7 D14 D21 D28
LNC-treated
group
24±3 33±3# 25±4# 23±1 20±2 24±2
NaCl control 22±4 33±3# 28±2# 22±2 23±3 20±8
#: p < 0.05 compared to the previous neighbouring time point (Bonferroni, ANOVA).
LNC: lipid nanocapsules
Table 6 Auditory brainstem response latency variance during test period (Mean±SEM)
Before D0 D7 D14 D21 D28
LNC-treated
group
0.74±0.03 0.88±0.02* 0.82±0.06 0.73±0.03 0.78±0.03 0.81±0.03
NaCl control 0.73±0.03 0.94±0.01* ## 0.77±0.01# 0.78±0.02 0.73±0.01 0.77±0.01
*: p < 0.05 comparison between the LNC-treated group and NaCl control (Bonferroni, ANOVA).
 #: p < 0.05 and ##: p < 0.01 when compared to the previous neighbouring time point (Bonferroni,
ANOVA).
5.4.2.2 Morphological results and cell viability detection
None of the animals exhibited middle ear infection during the treatment period. H&E
staining indicated the morphology of the cochlea and the vestibule were well preserved
following LNC treatment (Fig. 18). TUNEL-positive staining was consistently observed in
the interdental cells and stria marginal cells, OHCs, IHCs, and endothelial cells of the
semicircular canals in both the NaCl control and the LNC-treated rats (Fig. 18).
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Fig. 18 The morphology of the inner ear was well preserved in control group and lipid nanocapsule treated
group (A-D). TUNEL-positive staining was detected in stria marginal cells (arrows in E and G), interdental
cells (arrowheads in E and G), OHCs (E), and endothelial cells of semicircular canals (arrows in F and H)
both in the NaCl control and in the LNC treated rats (E-H). Red: TUNEL positive cells; Blue: DAPI. LNC:
lipid nanocapsules; OHC: outer hair cells. Scale bar=100 µm. (Figure 4 and Figure 5 G-J in Study V)
5.4.2.3 The preservation of neural elements in the inner ear
At D28, NF-200 staining indicated that the nerve fibers innervating the IHCs and OHCs,
the  SGCs,  and  the  CN  in  both  the  osseous  spiral  canal  and  the  modiolus  were  well
preserved in both the untreated and LNC-treated rats. The NF-200 fluorescence signals in
SGCs  (P  <  0.01)  and  in  the  CN  in  osseous  spiral  canal  (P  <  0.05)  of  the  LNC-treated
group were significantly weaker than that of the untreated group (Table 7). The S-100
signal intensities in the LNC-treated group were decreased in Deiter’s cells, SGCs and in
the  SL  when  compared  to  the  untreated  group.  However,  these  differences  were  not
statistically significant (p>0.05; Table 8).
Fig. 19 Distribution of synaptophysin and ribbon synapses in paraffin slides (A and B) and whole mounted
samples (C and D). Numbers in A and C mean the three rows of OHC (1 is close to modiolus; 3 is close to
SL). Red: synaptophysin. Green: ribbon synapses. Blue: DAPI. Scale bar=100 µm. (Figure 7 in Study V)
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Table 7 Comparison of NF-200 fluorescence intensity between LNC-treated and untreated
rats
IHC
(Mean±SEM)
SGCs
(Mean±SEM)
CN in osseous spiral canal
(Mean±SEM)
CN in modiolus
(Mean±SEM)
LNC-treated 5.71±0.51 1.69±0.07** 2.64±0.46* 2.41±0.32
Untreated 4.35±0.41 2.05±0.19** 4.21±0.88* 2.24±0.46
**: p < 0.01. *: p < 0.05 (Student’s t-test)
CN: cochlear nerve; IHC: inner hair cells; LNC: lipid nanocapsules; SGC: spiral ganglion cells
Table 8 Comparison of S100 fluorescence intensity between LNC-treated and untreated
rats
Deiter's cell
(Mean±SEM)
SGCs
(Mean±SEM)
SL
(Mean±SEM)
LNC-treated 3.53±0.89 2.00±0.10 2.96±0.31
Untreated control 5.89±1.33 2.38±0.17 6.03±0.52
Student’s t-test
CN: cochlear nerve; IHC: inner hair cells; LNC: lipid nanocapsules; SGC: spiral ganglion cells
The synaptophysin was completely preserved in both the LNC-treated groups and the non-
treated group. A typical distribution of synaptophysin was demonstrated within
varicosities of efferent endings on the basal pole of the three OHC rows and small dot-like
afferent  endings  at  the  bottoms of  IHCs.  Ribbon synapses  were  found at  the  bottoms of
IHCs in the LNC-treated and untreated rats [11.83±0.62 (mean±SEM) and 13.31±1.77
(mean±SEM), respectively]. However, this difference was not significant (p>0.05,
Student’s t-test; Fig. 19).
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6. DISCUSSION
6.1 Discussion of primary results
In general, observations of the distribution of nanocarriers in rat inner ear are difficult
because their signal can be confused with autofluorescence. Autofluorescence impairs the
detection of PM and LNC fluorescence signals in inner ear cells. In the whole-mounted
samples, autofluorescence was observed in the subcuticular cytoplasm of IHCs, border
cells, SGCs, strial marginal cells, SLFs, mesothelial cells of ST below the basilar
membrane, and the epithelial cells of the Reissner’s membrane; sparse autofluorescence
was observed in OHCs. The red emission and the green emission were highly co-localized
in the confocal image. In the LNC distribution study (Study IV), we did not quench the
autofluorescence with CuSO4. As a consequence, there was a certain degree of
autofluorescence  in  combination  with  fluorescence  from  the  LNCs.  In  this  study,  LNCs
were recognized by a lower degree of colocalization between the red and green
fluorescence (Fig. 16 and Fig. 17) when compared to autofluorescence signal. Decreased
colocalization also indicated that the LNCs may have been degraded in the inner ear cells
(Fig. 17).  Because we noticed autofluorescence, we used CuSO4 to quench the
autofluorescence in the PM studies and it proved the CuSO4 treatment does not decrease
the fluorescence of DiI encapsulated PMs.
A  comparison  of  topical  RWM  surface  delivery,  transtympanic  injection  and
cochleostomy provided information regarding the optimization of inner ear drug delivery.
Although transtympanic injection was not superior to topical RWM surface delivery of
PMs into the cochlea, it was more efficient in delivering PMs into the vestibulum.
However, none of these two methods was capable of introduce PMs into the spiral
ganglion or into Corti’s organ. Cochleostomy is the most efficient method to deliver PMs
into the inner ear compare to topical RWM surface delivery and transtympanic injection.
There are two pathways for PMs and LNCs to be transported from the middle ear cavity
into the inner ear in rats: through RWM to the ST, and through the oval window annular
ligament to the vestibular (Zou et al., 2010b; Zou et al., 2011b). Passage of PMs through
the  RWM can  be  achieved  by  functionalizing  the  PMs with  TAT peptide.  In  the  present
study, the TAT-PMs delivered via topical RWM surface showed more uptakes in RWM
and mesothelial cells of beneath Corti’s organ than either the ScrTAT-PMs or the
unlabeled PMs. TAT-PMs were also observed in outer sulcus cells and spiral ganglion,
whereas ScrTAT-PMs and unlabeled PMs were not.
The Tet1-PMs and the control PMs delivered via transtympanic injection exhibited no
targeting  to  either  SGCs  or  CN,  even  though  they  were  non-specifically  internalized  by
SLFs because SLFs do not express GT1b receptors. This may be due to insufficient
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number of PMs pass through the RWM. To support this idea we delivered PMs via
cochleostomy  and  the  PMs  were  present  spiral  ganglion  Schwann  cells  (SGSCs).  Tet1-
PMs delivered via cochleostomy were observed in axons as determined by the localization
of Tet1-PMs within or adjacent to neurofilaments. The Tet1 peptide is reported to bind to
the GT1b receptor, which is abundantly expressed in neuronal membranes in the central
nervous system and in peripheral nerve axolemmas (Ryu et al., 2002; Sheikh et al., 1999).
In  the  LNC  distribution  study  (Study  IV),  red  fluorescence  was  occasionally  apart  from
green fluorescence (Fig. 16 and 17), indicating that the LNCs were degradated in the inner
ear cells. But in which stage were the LNCs degradated needs further investigation. The
hearing threshold evaluation, the neural element analysis and the cell viability detection
showed no  hint  of  toxicity  of  the  LNCs in  the  rat  inner  ear.  In  another  study,  the  LNCs
administered via intracochlear injection did not cause hearing loss, nanocarrier
application-related cell death, or morphological changes in the inner ear (Scheper et al.,
2009). Our in vitro cell culture study using L929 cells and primary cochlear cells
demonstrated that the LNC toxicity is dose-dependant (Zhang et al., 2011). LNC toxicity
is primarily induced by the corona surfactant. However, higher surfactant concentrations
in  LNCs  do  not  lead  to  higher  cellular  toxicity.  An  in  vitro  study  demonstrated  that  the
toxicity of the LNCs is surfactant type dependent but not concentration dependent
(Maupas et al., 2011). In our study of the inner ear distribution and toxicity of LNCs,
Solutol® HS 15 and Lipoïd® S75–3 were used as corona surfactants, and the cells survived
with a relatively high concentration of LNCs. In L929 cells, an LC50 of 2.2 mg/mL was
observed, and in primary cochlear cell culture the survival rate at 1.5 mg/mL was 37.94%
(Zhang et al., 2011). The cell death is probably due to ‘overload phenomenon’, cell
functions will be impaired when the nanoparticles occupy a certain volume of the cell
(Moss,  2006).  In  macrophages,  overload  phenomenon  occurs  when  ? 6%  of  the  cell
volume is taken up by nanoparticles.
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6.2 Discussion of common results
6.2.1 Quenching autofluorescence in rat inner ear
The autofluorescence has a broad excitation/emission spectra, it can be detected with both
the 607/45 nm (red) and 525/50 nm (green) emission filters using confocal microscopy
(Kikugawa et al., 1997). The emission spectrum of autofluorescence ranges from 612 nm
to 513 nm, overlaps many fluorophores (Haralampus-Grynaviski et al., 2003). A2E (2-
[2,6-dimethyl-8-(2,6,6-trimethyl-1-cyclohexen-1-yl)-1E,3E,5E,7E-octatetraenyl]-1-(2-
hydroxyethyl)-4-[4-methyl-6-(2,6,6-trimethyl-1-cyclohexen-1-yl)-1E,3E,5E-hexatrienyl]-
pyridinium) is an isomer of a pyridinium bis-retinoid, which is thought to be the major
autofluorescence substance (Haralampus-Grynaviski et al., 2003). The quenching
mechanism of autofluorescence may be due to the cupric ion binding to amino acids close
to A2E and inducing energy transfer which is that the cupric ion absorbs the energy at
emission wavelength of the A2E without re-emitting the energy fluorescently (Gouanvé,
2007).
6.2.2 Comparison of the delivery methods to the rat inner ear (Study II)
The PMs and the LNCs delivered via topical RWM surface delivery were transported to
the perilymph of the ST through the RWM. The PMs delivered via transtympanic
injection can be transported to the perilymph via both the RWM and the oval window. The
RWM is a semi-permeable membrane. The epithelial layer of the RWM has tight
junctions (Goycoolea et al., 1997); the connective tissue layer and the endothelial layer are
loosely arranged. Therefore, it is possible that PMs pass through the epithelial layer via a
transcellular pathway; through the connective tissue and endothelial layers via an
intercellular pathway (Goycoolea et al., 1997). PMs delivered via RWM surface and
transtympanic injection were detected only in the epithelial layer of the RWM. However,
PMs  administered  through  cochleostomy  were  detected  in  all  three  RWM  layers  (Study
II). This finding suggests that when PMs were delivered into the cochlear perilymph, they
were 1) taken up by the endothelial cells, 2) diffused into the connective tissue core
through loose intercellular gaps of the endothelium, and then 3) internalized by the
epithelial cells of RWM. However, the PMs were unable to cross the tight junction of the
epithelial layer of the RWM and certain amount of them failed to pass through the cellular
membrane  when  they  were  administered  via  topical  RWM  surface  delivery  or
transtympanic injection. Variable transport efficacies of different agents across the RWM
have been reported in the literature. Topical RWM surface administration of gadolinium
results in poor loading of the nanoparticles in rat inner ear as shown by in vivo magnetic
resonance imaging (MRI) (Zou et al., 2010a). However, transtympanic injection of
PEGylated liposome nanocarriers encapsulating Gd-DOTA passed through the RWM
efficiently in vivo as determined by the Gd-DOTA MRI signal in the inner ear (Zou et al.,
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2010b). The variable efficacies of different substances in crossing the middle-inner ear
barriers may be dependent on the surface characteristics of the nanostructures.
As shown by a histological study in rats, the annular ligament across the stapedio-
vestibular joint is a porous structure (Ohashi et al., 2008). This structure is more
permeable to gadolinium than the RWM as determined by MRI studies (Zou et al., 2005;
2010a; 2011b). However, no difference was observed in the transport of liposome
nanoparticles between the oval window and the RWM as shown by an in vivo MRI study
using gadolinium as an imaging tag (Zou et al., 2010b).
Both transtympanic injection and topical RWM application failed to introduce the PMs
into  the  spiral  ganglion  or  Corti’s  organ.  Transtympanic  injection  was  more  efficient  in
delivering PMs into the vestibulum than topical RWM surface administration, even
though it was not superior to topical RWM application in terms of delivery into the
cochlea. Cochleostomy is the most efficient method to deliver PMs into these locations.
However cochleostomy is more traumatic than the other two methods. This method may
contribute to the development of new strategies for the deliver therapeutics directly to the
inner ear using modifications to existing cochlear implants.
6.2.3 Potential pathways of nanocarriers within the inner ear
Following entry into the perilymph through the RWM, the nanocarriers may enter the
modiolus by way of openings on the modiolar wall of the SV and ST. The carriers are also
penetrating to the SLFs through the mesothelial sheet of the SL facing the ST (Fig. 3)
(Rask-Andersen et al., 2006; Zou et al., 2008). Nanocarriers may subsequently migrate
within the modiolus and the lateral wall, reaching the higher turns of the cochlea (Salt et
al., 2005; Zou et al., 2009). In the SL, the nanocarriers may initially be internalized by
type III and IV SLFs through openings on the mesothelial cells that pave the SL in the ST
(Fig. 9 B and C) and then be transported along the SL. In the study of PMs delivered via
cochleostomy, the PMs were detected in the contralateral cochlea, suggesting that the PMs
may pass through the cochlear aqueduct (Hofman et al., 2005); this was conclusively
demonstrated in an in vivo MRI study (Zou et al., 2003a).
6.2.4 Peptide functionalization of the polymersomes
6.2.4.1 TAT-functionalized polymersomes
Because the PMs diffuse in perilymph to target the cochlear cells, more intense PMs in
cochlear cells indicates more PMs pass through the RWM and then presented in the
perilymph. It has been reported that the TAT peptide allows nanocarriers to cross the
epithelial monolayer via a transcellular pathway (Koch et al., 2005; Lindgren et al., 2004).
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We suppose that the TAT-PMs also pass through the RWM by similar mechanism. Under
traumatic circumstances, the penetration ability of TAT-conjugates was enhanced (Simon
et al., 2010a; Simon et al., 2010c).
6.2.4.2 Targeting of the Tet1-PMs to axons
The Tet1-PMs and the control PMs were observed in SGSCs identified by S100
immunostaining. Tet1-PMs were detected in nerve fibers in the TSF region as determined
by NF-200 immunostaining, but they were not observed in the neuronal soma. This may
be because of 1) the SGCs are enclosed by SGSCs, and there is poor communication
between these  cells;  2)  The  Tet1-PMs were  internalized  by  distal  axon compartments  of
SGCs, which can not be transported to the cell body compartment (Cui et al., 2007; Vance
et al., 1991).
Even though the free DiI can also be internalized by neurons (Sharma et al., 2000), the DiI
was  encapsulated  in  the  PMs  in  the  present  study.  In  addition,  the  two  control  PMs,
ScrTet1-PMs and unlabelled PMs, were not detected in the CN fibers. Furthermore based
on our unpublished result, passing through the RWM did not destroy the liposome
structure and the loaded Gd was not leaked out demonstrated by electronic microscopy.
The structure of PMs is stronger than liposomes, so we suspect that passing through RWM
do not destroy the structure of the PMs.
6.2.5 Toxicity study of lipid nanocapsules in rat inner ear
6.2.5.1 Hearing impairment
A threshold shift was observed at D0 in both LNC-treated and untreated groups. The
intervalpeakI-II at 50 dB SPL was also prolonged at D0. Both the threshold shift and the
intervalpeakI-II was recovered at D7 and remained stable during the four-week test period.
The instant hearing impairment may be caused by trauma to the middle ear during
operation.
Ribbon synapses consist of vesicles tethered by fine filaments in IHCs and vestibular hair
cells of the inner ear and in photoreceptors and bipolar cells of the retina (Nouvian et al.,
2006; Zenisek et al., 2004). The number of ribbon synapse is related to the sensitivity of
the mammalian cochlea (Meyer, 2009). Synaptophysin is located at the efferent nerve
endings  that  innervate  OHCs  and  IHCs.  It  is  an  important  synaptic  protein  for  hair  cell
physiology and often disintegrates prior to hair cell death (Bartolome et al., 2009). Ribbon
synapses and synaptophysin are two necessary parameters to verify any potential
contribution  of  hair  cell  toxicity  to  the  observed  threshold  shift.  The  ribbon  synapses  of
IHCs were quantified and the synaptophysin morphology in both IHCs and OHCs was
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evaluated at D0 (2 hours following LNC administration). In this study, LNC treatment did
not alter the number of ribbon synapses or the expression pattern of synaptophysin. The
threshold shift detected in animals following surgery may have been caused by trauma to
the middle ear.
6.2.5.2 Inner ear neural elements
Neurofilament 200 (NF-200) is a marker for myelinated afferent neurons, and it is a
structural protein of peripheral and central axons and plays a role in axonal transport
(Hoffman, 1975; Miller, 2002). NF-200 absence or degradation occurred in many
neurodegenerative diseases (Hwang, 2005; Posmantur, 1994; Posmantur, 2000). After
LNC treatment, neurofilaments innervating IHCs and OHCs were well preserved. In SGCs
and CN in osseous spiral canal, NF-200 levels were lower than the untreated control,
whereas, hearing of the rats was not affected at D28. These changes need to be verified in
future investigations.
S-100 is a marker of SGSCs. It was detected in inner sulcus cells, inner phalangeal cells,
SL, spiral limbus, and intermediate cells of inner ear (Hurley et al., 2007).  In this study S-
100 was also observed in Deiters’ cells, SGSCs, and the CN. S-100 is extensively
expressed in the nucleus and moderately expressed in cytoplasm. Distribution of S-100
was not affected by LNC treatment, but the immunostaining intensities in Deiter’s cells,
SGSCs and SLFs of the LNC-treated rats were decreased compare to the untreated group.
The mechanism needs further investigation. Pathologic level of S100 protein leads to
sustained activation, cell death and disease (Heizmann, CW 2005). However, the
decreased secretion of S100 proteins observed in the present study can rule out the
potential pathological response which needs to be investigated in the future.
6.2.5.3 Morphological results and cell viability detection
TUNEL staining detects DNA breaks caused by apoptosis, late necrosis and autolysis
(Gold, 1994). TUNEL-positive staining was observed in the normal inner ear in strial
marginal cells, interdental cells, the epithelial cells of SSCs, IHCs and OHCs; this
TUNEL-positive staining is due to autolysis that occurred during fixation (Nishizaki et al.,
1999). In this study, the TUNEL-positive staining pattern in the untreated cochleae was
similar to that observed in other reports. Furthermore, there was no difference in TUNEL
staining between the LNC-treated and untreated samples, indicating that LNC treatment
do not induce cell death in the inner ear.
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6.3 Future perspectives
Future work should concentrate on the use of LNCs and PMs as carriers of drugs or genes
to cure inner ear diseases. Furthermore, to reduce adverse effects, specific targeting of the
drug- or gene-loaded LNCs and PMs using functional peptides should be investigated and
comparison of general administration routes and the specific targeting routes of the drugs
or genes needs to be performed.
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7. SUMMARY AND CONCLUSIONS
The purposes of the present study were: 1) to evaluate the delivery efficacy of PMs into
the inner ear by different methods; 2) facilitating the outcome of the cell-penetrating
peptide-TAT; 3) determining the in vivo targetability of Tet1 peptide-functionalized PMs;
and 4) examining the distribution and biocompatibility of LNCs in the rat inner ear.
The following primary conclusions can be drawn from the results of the present studies:
1. Autofluorescence can be observed using confocal microscopy in rat inner ear,
and CuSO4 can quench the autofluorescence without affecting the visualization of
the PMs.
2. PMs can pass through the intact RWM and be internalized by the inner ear cells.
Different PM delivery methods resulted in different distribution patterns in the
inner ear cells. Cochleostomy was most efficient delivery method. Transtympanic
injection induced more PM internalization in the vestibulum than did topical
RWM delivery.
3. TAT-PMs exhibited more transportation through the RWM and internalization
by inner ear cells than did the scrambled or unlabeled PMs, indicating that the
TAT peptide increased penetration of the PMs through the RWM. In the second
set of experiments, auditory nerve targeting of Tet1-PMs administered via
cochleostomy was observed, conclusively demonstrating that the Tet1 peptide
facilitated neuronal targeting of the PMs.
4. LNCs can pass through the RWM and can be internalized by the inner ear cells,
and no evidence of toxicity was detected in the in vivo study.
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Fluorescent tags and ﬂuorophore-conjugated molecular probes have been extensively employed in
histological studies to demonstrate nanoparticle distribution in inner ear cell populations. However,
autoﬂuorescence that exists in the rodent cochleae disturbs visualization of the ﬂuorescent tags and
ﬂuorophore labeling. In the present work, we aimed to improve the visualization of ﬂuorescently tagged
nanoparticles and ﬂuorophore-labeled molecular probes by treatment with CuSO4 to quench auto-
ﬂuorescence in the rat inner ear. The in vivo study was performed on eight- to nine-month-old rats using
confocal laser scanning microscopy, and the in vitro study was carried out with DiI-tagged poly(ethylene
glycol) and poly(capro-lactone) polymersomes and different ﬂuorescent-labeling agents using a spec-
troﬂuorometer. The nanoparticles were intratympanically administered using either an osmotic pump or
transtympanic injection. Abundant autoﬂuorescence was detected in spiral ganglion cells (SGCs), stria
marginal cells, spiral ligament ﬁbrocytes (SL) and the subcuticular cytoplasm of inner hair cells (IHCs).
Sparsely distributed faint autoﬂuorescence was also visualized in outer hair cells (OHCs). The auto-
ﬂuorescence was eliminated by treatment with 1 mM CuSO4 (in 0.01 M ammonium acetate buffer) for 70
e90 min, while the ﬂuorescent tag in the nanoparticle was absolutely preserved and the labeling
ﬂuorescence signals of the molecular probes were mostly retained.
 2010 Elsevier B.V. All rights reserved.1. Introduction
Hearing loss is a major public health problem that ranks eighth
among the most common diseases in the EU. Traditional treatment
strategies for sensorineural hearing loss (SNHL) have not been very
successful. Bypassing the membranous borders and providing
direct contact with cochlear partitions, cochlear implantation is
a well-established method to restore the auditory pathway in
severe or profound hearing loss. However, hearing performance
after implantation is variable due to several factors (El-Hakim et al.,
2002; Gantz et al., 1993; Geers et al., 2002; Osberger et al., 2002).dole; DiI, 1,1’-Dioctadecyl-
; FITC, ﬂuorescein iso-
bryonic ﬁbroblast cell line;
GCs, spiral ganglion cells; SL,
C, strial marginal cells; StrV,
cyanate.
: þ358 3 35517700.
All rights reserved.Therefore, an ideal treatment for SNHL will depend on novel
techniques, such as gene or drug delivery using multifunctional
nanoparticles (MFNPs), in addition to cochlear implantation
(Pyykko, 2009).
In the Nanoear project, MFNPs were conjugated to several types
of ﬂuorescent tags, including Nile red, tetramethylrhodamine iso-
thiocyanate (TRITC), ﬂuorescein isothiocyanate (FITC), and 1,10-
Dioctadecyl-3,3,30,30-tetramethyl-indocarbocyanine perchlorate
(DiI), for their visualization in the cochlea (Scheper et al., 2009; Zou
et al., 2008; Zou et al., 2009a; Zou et al., 2009b). However, the
appearance of autoﬂuorescence from lipofuscin granules, which
result from the aging process, impairs the detection of the ﬂuo-
rescence signals of the MFNP targets (Feeney, 1978; Haralampus-
Grynaviski et al., 2003; Igarashi and Ishii, 1990; Rajawat et al.,
2009; Xu et al., 2008). Lipofuscin is widely found in human
cochlea (Ishii, 1977; Walther and Westhofen, 2007), chinchilla
cochlea (Bohne et al., 1990), guinea pig cochlea (Horner and
Guilhaume, 1995) and rat spiral ganglion (Igarashi and Ishii,
1990), which has complicated ﬂuorescent-labeling studies in the
inner ear.
Y. Zhang et al. / Hearing Research 269 (2010) 1e112Lipofuscin is a yellow ﬂuorescent aging pigment that is
commonly thought to be an end product of membrane lipid
autoxidation, which usually occurs in enteric neurons. In some
reports, it has been shown that the bluish ﬂuorescence of the lip-
ofuscin-like granules is generated in tissues during lipid perox-
idation, and the yellow ﬂuorescent pigments have been determined
to be proteinaceous (Kikugawa et al., 1997). Atomic force micros-
copy (AFM) of retinal pigment epithelium (RPE) from the human
eye has revealed that the surface of the lipofuscin granules is
smooth and comprised of substructures that are about 50 nm in
diameter and separated by thin boundary layers (Haralampus-
Grynaviski et al., 2003).
The emission spectrum of lipofuscin granules involves multiple
ﬂuorophores, and its emission maxima range from 612 nm to
513 nm (Haralampus-Grynaviski et al., 2003). Due to its broad
excitation/emission spectrum, it overlaps with commonly used
ﬂuorophores. Four kinds of distinct ﬂuorescence have been repor-
ted in a sodium dodecyl sulfate extract of male Wistar rat kidneys
fed normal diets: blue ﬂuorescence with excitation/emission
maxima at 360/440 nm, greenish ﬂuorescence at 460/530 nm,
yellow ﬂuorescence at 400/620 nm and 580/620 nm. The yellow
ﬂuorescence at 400/620 nm accumulates with aging, and its exci-
tation and emission maxima are close to those observed histo-
chemically under a ﬂuorescence microscope (Kikugawa et al.,
1997).
The ﬂuorescence of yellow ﬂuorescent lipofuscin can be
quenched by ferrous chloride and cupric sulfate (CuSO4) but
remains stable upon borohydride treatment (Kikugawa et al., 1997).
In previous studies, CuSO4 and Sudan Black B have been used to
eliminate autoﬂuorescence from the lipofuscin granules in sections
of human, monkey and rat neural tissue as well as in neuroﬁla-
ment-reactive neuron types in human small intestines (Brehmer
et al., 2004; Schnell et al., 1999).
In the current study, we investigated the distribution of greenish
and yellow autoﬂuorescence in the inner ear cellular populations of
adult SpragueeDawley (SD) rats using confocal laser scanning
microscopy. The interference of CuSO4 on the autoﬂuorescence and
DiI-tagged poly(ethylene glycol) and poly(capro-lactone) (PEG-
PCL) polymersomes and the commonly used labeling ﬂuorophores
FITC and TRITC was analyzed using a spectroﬂuorometer. The
visibility of ﬂuorescently tagged nanoparticles and ﬂuorophore-
labeled molecular probes was evaluated in the rat inner ear.
2. Materials and methods
2.1. Manufacturing and characterization of PEG-PCL polymersomes
Anhydrous N, N-dimethylformamide, poly(ethylene glycol)-
block-poly(e-capro-lactone) methyl ether, PEG average Mnw5000,
and PCL averageMnw5000 (PEG5K-b-PCL5K) was purchased from
SigmaeAldrich (USA). 1,10-Dioctadecyl-3,3,30,30-tetramethyl-
indocarbocyanine perchlorate (DiI) was obtained from Invitrogen.
Phosphate buffered saline (PBS) was made using phosphate buff-
ered saline tablets (Oxoid, UK) and H2O (puriﬁed using a Milli-Q
Ultrapure Water Puriﬁcation System [resistance of 18.2 M U cm at
25 C]). Dialysis tubing with a 12e14 kDa cutoff and 6.3 mm
diameter was supplied from Medicell International Ltd. (UK).
Dynamic light scattering was performed on a Coulter N4 Plus
particle sizer using N4 Plus version 1.10 software for data analysis.
A 0.1 mg/mL solution of DiI in anhydrous N, N-dimethylforma-
mide was prepared. PEG5000-b-PCL5000 (6.0 mg) was dissolved in
the DiI-DMF solution (0.4 mL), and the solutionwas sonicated until
complete dissolution. The polymer solution was then added drop-
wise (w1 drop every 8 s) to PBS (1.60 mL) while stirring. The
sample was dialyzed against PBS (400 mL), and the buffer solutionwas replaced four times over the course of 48 h. Analysis by
dynamic light scattering revealed that the typical size of the NPs
was 83.517.6 nm and that they were stable in solution for at least
two weeks.
2.2. Impact of ﬁxation on polymersome internalization
In order to evaluate the potential disturbance of free extracel-
lular polymersomes on the observation of internalization during
specimen dissection, PEG-PCL polymersome internalization was
compared between live and pre-ﬁxed NIH3T3 cells (mouse
embryonic ﬁbroblast cell line). NIH3T3 cells were plated into
a 4-well Lab-TekII Chamber Slide System (Nalge Nunc Interna-
tional, Naperville, USA) containing 1.0 ml deﬁned medium/well
(Dulbecco’s modiﬁed eagle’s medium supplemented with 10% fetal
bovine serum and 1% antibiotic-penicillin/streptomycin solution).
The cells were cultured at 37 C in a CO2 incubator until 85%
conﬂuence reached. PCL-PEG polymersomes with 100 fold dilution
were added to the medium of either live cells or pre-ﬁxed cells
(4% paraformaldehyde, PFA) and incubated for 12 h. After washing
with 0.01 M PBS, ﬁxation with 4% PFA (live cells), and staining with
40,6-diamidino-2-phenylindole (DAPI, 10 mg/ml) for 10 min, the
cells were mounted with Fluoromount (SigmaeAldrich, USA) for
confocal microscopy. Each test (live cells and pre-ﬁxed cells) was
repeated in 6 wells.
2.3. Animals
Sixteen eight- to nine-month-old male SD rats with normal
Pryer’s reﬂexes and weighing 600e700 g (supplied by the experi-
mental animal unit, University of Tampere) were used in this study.
All were treated in accordancewith the directives of the local ethics
committee of the University of Tampere (permission: LSLH-2006-
4143/Ym23). The left or right bulla of each animal was randomly
selected for analysis. Five cochleae were used in the auto-
ﬂuorescence study, ﬁve were stained with FITC-conjugated phal-
loidin, four were stained with TRITC-conjugated phalloidin, and
twowere stained with an antibody against Neuroﬁlament-200 (the
secondary antibody was conjugated with FITC) using whole
mounting method. Two cochleae were employed in parafﬁn
embedding, sectioning, and immunostaining with an antibody
against Neuroﬁlament-200 (the secondary antibody was conju-
gated with Alexa Fluor-568). In all of the ﬂuorescence tissue-
staining processes, half of each cochlea was treated with CuSO4 and
the other half was not treated. Twelve bullae from six rats were
used in the in vivo investigation of the distribution of PEG-PCL
polymersomes in the inner ear and the impact of CuSO4 treatment
on the visualization of PEG-PCL polymersomes. The PEG-PCL pol-
ymersomes were either applied to the inner ear by osmotic pumps
(1003D, Alzet, Canada) for 3 days (6 cochleae) or by transtympanic
injection (40 ml) for 3 days (4 cochleae) or 5 days (2 cochleae). The
injection volumewas deﬁned according to the literature report that
an average volume of SD rat middle ear cavity is 42 ml (Kania et al.,
2006). All experimental procedures were performed under general
anesthesia, induced andmaintained by intraperitoneal injections of
a mixture of Domitor (1 mg/ml, Domitor, Orion, Finland) and
Ketalar (50 mg/ml, Pﬁzer, UK) (0.6 ml for induction and 0.3 ml for
maintenance) (Domitor:Ketalar ¼ 1:2).
2.4. Administration of PEG-PCL polymersomes to the inner ear
All of the PEG-PCL polymersome administrations were per-
formed under an operating microscope. In the osmotic pump
delivery approach, surgical towels were autoclaved and operating
instruments were sterilized by a bead sterilizer (STERI 250,
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sterilized by 70% ethanol. The animals were placed on a thermo-
regulated heated pad covered with surgical towel in a rightward
lateral position. A retro-auricular incision was used to expose the
left bulla after local analgesia with 1% lidocaine. A hole was drilled
on the bulla with a 2-mm diameter burr. After visualizing the
stapedial artery, the round window membrane was identiﬁed
above the artery. A small piece of gelatin sponge (Gelfoam)
pledget soaked in PEG-PCL polymersomes (around 8 mm3 after
soaking with an NP solution) was placed near the round window
niche. The micro-osmotic pump was ﬁlled with 100 ml of PEG-PCL
polymersomes and connected to a catheter (PE60, Becton Dick-
inson and Company) preﬁlled with the same solution. The catheter
tip was placed onto the gelatin sponge, the catheter was ﬁxed on
the bulla with Phosphate Cement (Heraeus Kulzer GmbH,
Germany), and the osmotic pumpwas implanted subcutaneously in
the neck. In the transtympanic injection, an approximately 1-mm
incision was made on the ﬁrst quadrant (anterior upper quadrant)
of the tympanic membrane by a 27 gauge needle to remove any
potential air bubbles. Next, 0.04 ml of PEG-PCL polymersomes was
injected into the middle ear cavity via the second quadrant of the
tympanic membrane. During the procedure, the animal eyes were
protected by Terra-Cortril-P (Pﬁzer, UK). Atipamezole hydrochlo-
ride (2 mg/kg) was injected i.p. immediately after the operation to
accelerate the animals’ recoveries from anesthesia. Saline (2 mL)
was administered through subcutaneous injection on the neck.
RIMADYL (1.0 mg/kg, Pﬁzer, UK) was injected to relieve pain. Baytril
(10 mg/kg, Orion, Germany) was injected i.p. once a day to prevent
potential middle ear infection.
2.5. Autoﬂuorescence and speciﬁc ﬂuorescence observation
The rats were anaesthetized using 0.8 mg/kg of medetomidine
hydrochloride (Domitor, Orion, Finland) and 80 mg/kg of ketamine
hydrochloride (Ketalar, Pﬁzer, UK). The bullae were ﬁxed by cardiac
perfusion with 4% paraformaldehyde (Merck, Germany) [0.01 M
PBS containing 0.6% (v/v) heparin, pH 7.4 to remove the blood
before ﬁxation]. No inﬂammation was found in the middle ear
cavity of any animals. The isolated cochleae were rinsed with tap
water for 1 min to remove potential free PEG-PCL polymersomes
remained on the outer surface and further stored in the ﬁxation
solution for 2 h. After washing with PBS, the basal turn, middle
turn, and apex (include Corti’s organ, spiral ligament, and mod-
iolus) of the cochlea and the round window membrane and
ampullae of the vestibule were isolated. The tectorial membrane
was removed under a stereomicroscope. The specimens were
stained with 40,6-diamidino-2-phenylindole (DAPI) (10 mg/ml, Sig-
maeAldrich, USA) for 10min at room temperature in the dark. After
washingwith PBS, the specimens were placed on 8-well slides (Cel-
Line/Thermo scientiﬁc, USA) and mounted with Fluoromount
(SigmaeAldrich, USA) for confocal microscopy.
2.6. Effect of CuSO4 treatment on the autoﬂuorescence,
ﬂuorescencently tagged nanoparticles, and ﬂuorophore-labeled
molecular probes
2.6.1. Time response of the labeling ﬂuorescence and nanoparticle
tag to CuSO4 treatment using a spectroﬂuorometer
DiI-tagged PEG-PCL polymersome nanoparticles and FITC/
TRITC-conjugated phalloidin solutions were prepared with 1 mM
CuSO4 in 0.01 M ammonium acetate buffer (pH 5.0). The ﬁnal
concentration of FITC/TRITC-conjugated phalloidin was 0.25 mg/ml
and the ﬂuorescence intensity was measured at different time
points (0, 30, 60, 90, and 120 min) by a spectroﬂuorometer (Photon
Technology International, UK, serial number: 2406) equipped withFeliX32 operating software. For the PEG-PCL polymersome nano-
particles, the ﬂuorescence intensity was measured at 0 and 90 min.
The reference solution was made with 1 mM CuSO4 in 0.01 M
ammonium acetate buffer (pH 5.0). For the untreated control, FITC/
TRITC-conjugated phalloidin solutions were prepared with 0.1 M
PBS to a ﬁnal concentration of 0.25 mg/ml and weremeasured at the
same time points as the CuSO4-treated samples. The reference
solution was made with PBS. The excitation/emission wavelengths
were 494 nm/517 nm for FITC-conjugated phalloidin, 540 nm/
572 nm for TRITC-conjugated phalloidin, and 543 nm/568 nm for
PEG-PCL polymersome nanoparticles. The areas of the emission
spectra within the wavelength range of 509e529 nm for FITC-
conjugated phalloidin, 562e582 nm for TRITC-conjugated phal-
loidin, and 562e572 nm for PEG-PCL polymersome nanoparticles
were selected as deﬁned signal intensities. The ﬂuorescence signal
intensities of the CuSO4-treated and untreated samples were cor-
rectedwith the CuSO4 and PBS references, respectively. Considering
a signal intensity of 1 at 0 min treatment, the rates of the signal
intensities of FITC/TRITC-conjugated phalloidin solutions were
acquired at 30, 60, 90 and 120 min and compared with that at
0 min. Five trials were repeated for each study.
2.6.2. Histology study
First, the interaction of the CuSO4 treatment on ﬂuorescent tags
of nanoparticles (NPs) was investigated using the DiI-tagged PEG-
PCL polymersomes as a model system. After washing with PBS, the
lateral wall of the cochlea was dissected in PBS and the tectorial
membrane was removed from the Corti’s organ under a stereomi-
croscope. The specimens of the lateral wall, modiolus and basilar
membrane were cut into pieces corresponding to the basal turn,
middle turn, and apex. In addition, the ampullae of the semicircular
canals were isolated. After treatment with CuSO4 for 90 min, the
specimens were washed with PBS, nuclei counterstained with
10 mg/ml of DAPI, washed again with PBS, and mounted with Flu-
oromount for confocal microscopy.
Since identifying spiral ganglion cells using immunoﬂuores-
cence techniques has been applied in the Nanoear study, the
interaction of CuSO4 treatment during the antibody staining
procedure was analyzed using a primary antibody against Neuro-
ﬁlament-200 and a secondary antibody conjugated with FITC (Zou
et al., 2008). The inner ear specimens were treated with 0.5% Triton
X-100 for 15 min, washed with pure water (Millipore, USA), incu-
bated with goat serum (1:20 in 0.1% BSA), incubated with rabbit
anti-Neuroﬁlament-200 (NF-200) (SigmaeAldrich, USA, 1:200 in
0.1% BSA) overnight at 4 C, washed with PBS-T (PBS containing
0.1% Tween 20), incubated with FITC-labeled goat anti-rabbit IgG
(1:400, SigmaeAldrich, USA) for 1 h at room temperature, washed
with PBS-T and then stained with 10 mg/ml DAPI for 10 min. After
washing with PBS, the lateral wall, basilar membrane, and osseous
spiral lamina of each turnwere cut into two parts. One piece of each
turn was treated with 1 mM CuSO4 in 0.01 M ammonium acetate
buffer (pH 5.0) for 90 min, washed with pure water, and mounted
with Fluoromount for confocal microscopy; the other part was set
as an untreated control and directly mountedwith Fluoromount for
confocal microscopy. Immunoﬂuorescence staining for NF-200 was
also performed on parafﬁn sections of two EDTA-decalciﬁed bullae
using the standard procedure.
The cellular skeleton including the hair cells was visualized by
probing for F-actinwith FITC/TRITC-conjugated phalloidin, as in the
Nanoear project (Zou et al., 2008). The effects of CuSO4 treatment
on FITC/TRITC-conjugated phalloidin were further evaluated. After
washing with pure water, the basal turn, middle turn and apex
(including the lateral wall, basilar membrane, and osseous spiral
lamina) of the cochlea and the ampullae of the semicircular canals
were isolated, and the tectorial membrane was removed. The
Fig. 1. Internalization of PCL-PEG polymersomes in NIH3T3 cells. Panel A, PEG-PCL
polymersomes appeared in cytoplasm in abundant quantity (arrow). Panel B, No PEG-
PCL polymersome was internalized by pre-ﬁxed NIH3T3 cells, but sparsely aggregated
in the extracellular region of the slide (arrowhead). Scale bar ¼ 10 mm.
Y. Zhang et al. / Hearing Research 269 (2010) 1e114specimens were incubated with 50 mg/ml of FITC/TRITC-conjugated
phalloidin (SigmaeAldrich, USA) at room temperature for 45 min
and then stained with DAPI (10 mg/ml) for 10 min. Each turn of the
cochlear tissues was cut into two parts. One part was treated with
CuSO4 for 70 or 90 min and mounted with Fluoromount for
confocal microscopy after washing with PBS-T, and the other part
was directly mounted for confocal microscopy as the untreated
control.
2.7. Confocal microscopy
The whole mount samples were observed under an Olympus
microscope IX70 installed with ANDOR IQ. The excitation ﬁlters
were 488 nm (blue excitation) and 568 nm (green excitation) with
an AreKr laser as the excitation source. The corresponding emis-
sion ﬁlters were 525/50 nm (FITC) and 607/45 nm (TRITC and DiI).
DAPI was excited with a 340e380 nm ﬁlter and detected using
a 500 LP ﬁlter. For 3D scanning, the interslice thickness was 0.5 mm.
For semi-quantiﬁcation, the mean ﬂuorescence signal intensities of
the irregular IHC hair bundles, the ‘V-shaped’ OHC hair bundles
(single row) and the strial marginal cells of each confocal graph
were measured by Image J software (1.41). A background area was
chosen as the reference in each confocal micrograph. The ﬁnal
signal/noise ratio was acquired by dividing the mean signal inten-
sity value of the target region by the mean noise intensity value of
the reference area.
The colocalization of autoﬂuorescent plots triggered with
different wavelengths under confocal microscopy was analyzed
using Image J software (1.41).
2.8. Statistics
Statistical analyses were performed using the SPSS 11.5 software
package. For confocal microscopy studies, the signal/noise values of
IHC hair bundles, OHC hair bundles and stria marginal cells
between the CuSO4-treated and untreated specimens were
analyzed using Student’s t-tests. For the spectroﬂuorometer study,
the ﬂuorescence signal intensities and the remaining rates of the
ﬂuorescence signal intensities between CuSO4-treated and
untreated samples were compared using Student’s t-tests at
different time points. Changes in the ﬂuorescence signal intensities
and the remaining rates of the ﬂuorescence intensities between
two adjacent time points in each group were analyzed with
a Bonferroni correction of the analysis of variance (ANOVA).
Differences were considered to be statistically signiﬁcant at
p < 0.05.
3. Results
3.1. Impact of ﬁxation on polymersome internalization
in NIH3T3 cells
In live NIH3T3 cells, PEG-PCL polymersome internalization was
repeatedly observed in cytoplasm with the typical appearance of
vesicles (Fig. 1A). However, the internalization was completely
abolished by the ﬁxation of the cells with 4% PFA (Fig. 1B).
3.2. Autoﬂuorescence in the rat inner ear
Abundant autoﬂuorescence dots were observed in the sub-
cuticular cytoplasm of inner hair cells (IHCs) and Border cells.
Obvious autoﬂuorescence dots were also detected in SGCs, strial
marginal cells, spiral ligament ﬁbrocytes, mesothelial cells of the
scala tympani below the basilar membrane, and epithelial cells of
the Reissner’s membrane. A sparse distribution of autoﬂuorescencewas found in outer hair cells (OHCs). However, no autoﬂuorescence
was discovered in the supporting cells, including Deiters’ cells and
Hensen cells. A variable phenotype of autoﬂuorescence was
observed, which was larger in size and less dense in the Reissner’s
membrane and larger and denser in type I SGCs in comparison to
other cell populations showing smaller dots homogeneously
distributed in the cytoplasm (Fig. 2D, H, and L).
Brilliant red autoﬂuorescence was observed with the 607/45 nm
emission ﬁlter, while obscure yellowish-green autoﬂuorescence
was visualized with the 525/50 nm emission ﬁlter. Quantiﬁcation
was performed on the confocal microscopy images by measuring
the colocalization of the autoﬂuorescent dots with the above-
mentioned ﬁlters. The overlap rates of autoﬂuorescence triggered
by both wavelengths were 97.16% in spiral ligament ﬁbrocytes,
96.55% in SGCs, 93.77% in stria marginal cells, and 95.40% in IHCs
(Fig. 2).
3.3. The effect of CuSO4 treatment on the labeling ﬂuorescence
using a spectroﬂuorometer
The ﬂuorescent signal intensity of PEG-PCL polymersomes was
not changed after treated with CuSO4 for 90 min when compared
with the untreated control (Fig. 3A and B; p > 0.05).
The ﬂuorescence signal intensities between the CuSO4-treated
TRITC-conjugated phalloidin and the untreated control were
compared at time points of 0, 30, 60, 90, and 120 min. The ﬂuo-
rescent signal was not signiﬁcantly inﬂuenced by treatment with
CuSO4 (p> 0.05; Fig. 3C). In addition, the signal intensities between
the corresponding neighboring time points of either the CuSO4-
treated samples or the control were not signiﬁcantly different
Fig. 2. Appearance of autoﬂuorescence in the rat cochleae and the effect of treatment with CuSO4 demonstrated by confocal microscopy. Panels AeD show the red autoﬂuorescence
using the 607/45 nm emission ﬁlter. Panels EeH show the greenish autoﬂuorescence using the 525/50 nm emission ﬁlter. Panels IeL demonstrate the colocalization of the red
autoﬂuorescence and the greenish autoﬂuorescence (the overlap rate analyzed by Image J 1.41). Panels A, E, and I depict the abundant autoﬂuorescent dots in IHCs with a red and
the greenish ﬂuorescent overlap rate of 95.40% (z-series pictures; down pointing arrow: IHC; right pointing arrow: OHC). Panels B, F, and J show the autoﬂuorescence in the stria
marginal cells with a red and green overlap rate of 93.77%. Panels C, G, and K demonstrate the autoﬂuorescence in the spiral ligament ﬁbrocytes with a red and green overlap rate of
97.16%. Panels D, H, and L show the large and irregular lipofuscin granules in SGCs (arrows) and small lipofuscin in the spiral ganglion satellite cells (arrow heads) with a red and
greenish overlap rate of 96.55%. Panels M (z-series picture), N, O and P show the disappearance of autoﬂuorescence in IHC (M), stria marginal cells (N), spiral ligament ﬁbrocytes (O),
and SGCs (P) after treatment with CuSO4 for 90 min (Blue: nucleus stained with DAPI; Panels IeP: RGB pictures). Scale bar ¼ 10 mm.
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samples at 30 min (p < 0.01, Bonferroni of ANOVA) and 60 min
(p < 0.05) and the untreated control at 30 min (p < 0.01) were
signiﬁcantly decreased in comparison with earlier time points
(Fig. 3D). There was no statistically signiﬁcant decay in the rates of
the remaining ﬂuorescent signals between the CuSO4-treatment
samples and the untreated control at 0, 30, 60, 90 and 120 min
(p > 0.05; Fig. 3D). At 120 min post-treatment, 43.40 and 43.52% of
the ﬂuorescence signal intensity remained in the CuSO4-treatment
samples and the untreated control, respectively, compared to the
signal intensity of the untreated control at 0 min.
The ﬂuorescence signal of the FITC-conjugated phalloidin was
signiﬁcantly decreased immediately after treatment with CuSO4 at
0 min (p < 0.01, Student’s t-test), and this decrease was maintained
until 30 min after treatment (p < 0.05, Student’s t-test) (Fig. 3E).
Analysis of the ﬂuorescence signal between neighboring time
points revealed no signiﬁcant decay in the untreated control, which
ruled out ﬂuorescence blanching (p > 0.05, Student’s t-test). In the
CuSO4-treated samples, a signiﬁcant decay in the remaining rate
was observed at 30 min post-treatment (Fig. 3F; p < 0.01,Bonferroni of ANOVA). No further signiﬁcant decay was detected at
later time points. At 120 min post-treatment, 1.27 and 51.74% of the
ﬂuorescence signal intensity remained in the CuSO4-treated
samples and the untreated control, respectively, compared to the
signal intensity of the untreated control at 0 min.3.4. CuSO4 treatment quenches autoﬂuorescence while preserving
the nanoparticle tag and labeling ﬂuorescence in the rat inner ear
At 90 min post-treatment, no autoﬂuorescence was visible in
the tissue (Fig. 4aee). However, in the specimens treated with
CuSO4 for 70 min, autoﬂuorescence disappeared in IHCs, meso-
thelial cells of the scala tympani below the basilar membrane, and
stria marginal cells. In the cochlear spiral ligament ﬁbrocytes and
vestibule, autoﬂuorescence disappeared in most of the cells.
However, less condensed dots were still detected in a few of the
cells, which were mainly located in the central zone of the spiral
ligament. In SGCs, autoﬂuorescence remained, but with greatly
reduced intensity (Fig. 4D, d).
Fig. 3. Impact of CuSO4 treatment on the ﬂuorescent signal intensities of FITC/TRITC-conjugated phalloidin. Panels A and B show that there was no statistically signiﬁcant
differences in the ﬂuorescent signal intensities and remaining rates of DiI-tagged PEG-PCL polymersomes between the CuSO4 treatment and untreated control at time points of
0 min and 90 min treatment (p > 0.05, Student’s t-test). Panels C and D shows that there was no signiﬁcant difference in the ﬂuorescent signal intensities and remaining rates of
TRITC-conjugated phalloidin between the CuSO4 treatment and untreated controls at each time point (p > 0.05, Student’s t-test). Panel E shows that there were statistically
signiﬁcant differences in the ﬂuorescence signal intensities of FITC-conjugated phalloidin between the CuSO4-treated and untreated samples at each time point (p < 0.01, Student’s
t-test). Panel F shows that there were signiﬁcant differences in the FITC ﬂuorescent signal remaining rates between the CuSO4-treated and untreated samples at 30 min (p < 0.01,
Student’s t-test) and 60 min (p < 0.01, Student’s t-test). Comparison of the ﬂuorescent signal between each deﬁned time point and its earlier neighboring time point within the
group showed the following results: *p < 0.05 in untreated control; #p < 0.05 in CuSO4-treated group; **p < 0.01 in untreated control; ##p < 0.01 in CuSO4-treated group
(Bonferroni of ANOVA).
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Fig. 4. Visualization of F-actin labeled by FITC (green)/TRITC (red)-conjugated phalloidin, and the autoﬂuorescence that was eliminated by CuSO4 treatment in the inner ear cell
populations. Panels AeH show the untreated controls. Panels aeh show the specimens treated with 1 mM CuSO4 for 70 min (f) or 90 min (a, b, c, d, e, g, h) after staining with FITC/
TRITC-conjugated phalloidin. The F-actin labeling remained while the autoﬂuorescence was eliminated. Panels A and B show the autoﬂuorescence in the subcuticular cytoplasm of
IHCs and the Border cells. Panel C shows that the autoﬂuorescence in OHCs. Panel D shows the large autoﬂuorescent dots in SGCs. Panel E shows the autoﬂuorescence in the stria
marginal cells. Panel F shows the autoﬂuorescence in the hair cells of the ampullae. Panels G, g, H and h show visualization of F-actin labeling by TRITC-conjugated phalloidin on
strial marginal cells (G) and Inner hair bundles (H) are not affected after CuSO4 treatment (g and h) (Asterisks: hair bundles of IHCs; arrows: autoﬂuorescent dots in IHCs; arrow
heads: autoﬂuorescence disappeared after CuSO4 treatment; Blue: nucleus stained with DAPI; B, b, C, c: z-series image). Scale bar ¼ 10 mm.
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vesicles when internalized. They were detected on the outer
epithelial layer of the round windowmembrane as being dispersed
in the cytoplasm at 3 days post-administration via osmotic pump
and were homogeneous in the peri-nuclear region at 3 days and 5
days post-intratympanic injection (Figs. 5A, F and 6). There were
sparse nanoparticles in the connective tissue core of the round
windowmembrane in all animals (Fig. 5C). Nanoparticles were also
found in mesothelial cells of scala tympani and suprastrial area of
scala vestibuli, Capillaries of the stria vascularis of the ﬁrst turn at 3
days post-administration via osmotic pump (Fig. 5B). The PEG-PCL
polymersome nanoparticles were visualized in themesothelial cellsof the scala tympani beneath the Corti’s organ (Fig. 5I), cells within
the suprastrial area (Fig. 5H), and capillary of the stria vascularis
(Fig. 5G) of whole coil on 3 day and 5 day post-transtympanic
injection. PEG-PCL polymersomes were also detected in utricle,
saccule, and ampulla of the vestibule (Fig. 5J). Polymersomes were
also observed in auditory nerve region and spiral ganglion region
(Figs. 5D, E and 6) on 5 day post-transtympanic injection. No PEG-
PCL polymersomes were detected in IHCs, OHCs, supporting cells of
Corti’s organ, and marginal cells of stria vascularis.
Neuroﬁlament-200 was immunoﬂuorescently observed in the
bodies of SGCs, cochlear nerve ﬁbres, tunnel ﬁbres, and nerve
endings on IHCs and OHCs (Fig. 7). The immunoﬂuorescence
Fig. 5. The distribution of the PEG-PCL polymersomes in the inner ear cell populations after CuSO4 treatment. Panels AeC, showed the distribution of polymersomes at 3 days post-
administration via osmotic pump. Panels DeJ, showed the distribution of polymersomes at 5 days post-transtympanic injection. Panels A and F showed the distribution of the
nanoparticles in the outer epithelial layer of the round window membrane at 3 days (panel A) and 5 days (panel F). Panels B and G showed the distribution of nanoparticles in the
capillary endothelial cells of the stria vascularis at 3 days (panel B) and 5 days (panel G). The nuclei of the endothelial cells are indicated by arrows. Panel C showed the connective
tissue core of the round window membrane without nanoparticle at 3 days. Panels D, E, H, I, and J demonstrated the nanoparticle appearance in the auditory nerve region (D), the
spiral ganglion region (E), ﬁbrocytes within the suprastrial area (H), mesothelial cells beneath the Corti’s organ (I) and cells in the vestibule (J), respectively. The vessel walls in
Panels B and G were outlined with dashed white lines by Photoshop. (Red: PEG-PCL polymersome targeted with DiI; Blue: nucleus stained with DAPI). Scale bar ¼ 10 mm.
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(Fig. 7). Because of the irregular distribution of Neuroﬁlament-200
in the tissue, quantiﬁcation was not performed.
Both FITC-conjugated phalloidin and TRITC-conjugated phal-
loidinwere used to label the hair bundles of the IHCs and OHCs, the
bodies of the inner and outer pillar cells, the intercellular junctions
of stria marginal cells, and the cytoplasm of SGCs. The CuSO4
treatment did not affect the visualization of the labeled F-actin by
either FITC-conjugated phalloidin or TRITC-conjugated phalloidin.
After treatment with CuSO4 for 90 min, the ﬂuorescence intensity
(signal/noise) of FITC labeling showed a statistically signiﬁcant
difference in IHCs and stria marginal cells (p < 0.01, Student’s t-Fig. 6. PEG-PCL polymersome distribution in inner ear cell populations was drawn in
green using Photoshop. 1: suprastrial area. 2: mesothelial cells lining bony labyrinth of
SV. 3: stria vascularis. 4: mesothelial cells beneath Corti’s organ. 5: cells of auditory
nerve. 6: cells in spiral ganglion region. Scale bar ¼ 100 mm.test), but not in OHCs (p > 0.05, Student’s t-test) (Fig. 3; Table 1).
The TRITC labeling ﬂuorescence intensity (signal/noise) was
signiﬁcantly decreased in the stria marginal cells (p < 0.01,
Student’s t-test) but was not affected in the IHCs or OHCs (p > 0.05,
Student’s t-test; Table 2).
4. Discussion
In this study, abundant autoﬂuorescence was observed in the
subcuticular cytoplasm of IHCs and border cells. Obvious auto-
ﬂuorescence was detected in SGCs, strial marginal cells, spiral
ligament ﬁbrocytes, mesothelial cells of scala tympani below the
basilar membrane, and epithelial cells of the Reissner’s
membrane. Additionally, a sparse distribution of auto-
ﬂuorescence was found in OHCs. In contrast, no autoﬂuorescence
was found in Deiters’ cells or Hensen cells. Our observation of
autoﬂuorescence in rat cochlea was different from a report using
chinchilla, which demonstrated more autoﬂuorescence distribu-
tion in OHCs and much less in IHCs (Bohne et al., 1990). These
results suggest differential metabolism and aging processes in the
hair cells of different species (Feeney, 1978; Haralampus-
Grynaviski et al., 2003; Igarashi and Ishii, 1990; Kikugawa et al.,
1997; Rajawat et al., 2009; Xu et al., 2008). Our observation of
autoﬂuorescence in SGCswas in accordancewith previous reports
regarding theirmorphology and subcellular distribution (Igarashi
and Ishii, 1990).
The high overlap of the red and greenish autoﬂuorescence
(97.16% in the SL, 96.55% in the SGCs, 93.77% in the StrV, 95.40% in
the IHCs), which was detected with both the 607/45 nm (red) and
525/50 nm (green) emission ﬁlters using confocal microscopy,
supports a previous study, which found that lipofuscin (auto-
ﬂuorescence) has a broad excitation/emission spectra (Fig. 1)
(Kikugawa et al., 1997), whereas the ﬂuorophores (TRITC/FITC) have
narrow excitation/emission spectra. Under the green emission
ﬁlter, it was visually easier to distinguish the autoﬂuorescence from
the speciﬁc green ﬂuorophores, because the autoﬂuorescence
appeared yellow and the speciﬁc ﬂuorescence was pure green.
Fig. 7. Visualization of the immunoﬂuorescent staining of neuroﬁlament-200 (NF-200) in the inner ear when the autoﬂuorescence was eliminated by CuSO4 treatment. Panel A
shows a z-series image of the appearance of autoﬂuorescence in IHCs (arrowhead) and NF-200 staining on nerve ﬁbres (arrow) in the Corti’s tunnel innervating OHCs in the no
treatment control. Panel B shows a z-series image of NF-200 staining of nerve ﬁbres (arrow). The ﬂuorescence of NF-200 staining remained while the autoﬂuorescence disappeared
in IHCs (arrowhead) after treatment with CuSO4 for 90 min. Panel C demonstrates the appearance of autoﬂuorescence (red dots) and NF-200 staining (green) in SGCs (nuclei of SGCs
are indicated by asterisks) of no treatment controls. Panel D shows the NF-200 staining remains in SGCs while the autoﬂuorescent dots disappear after treatment with CuSO4. Panel
E shows NF-200 staining on nerve ﬁbres (arrow) in the Corti’s tunnel innervating OHCs in parafﬁn embedded slices (z-series image of 20-mm thickness parafﬁn section). Panel F
shows NF-200 staining of the cytoplasm (arrow head) and processes (arrow) of SGCs (nuclei are indicated by asterisks) and the nerve ﬁbres (arrow) in parafﬁn embedded slices.
(Blue: nucleus stained with DAPI). Scale bar ¼ 10 mm.
Table 1
Fluorescent signal changes of FITC-phalloidin binding in the cochlear cell pop-
ulations induced by CuSO4.
Groups IHC OHC StrMC
n Means  SEM n Means  SEM n Means  SEM
No treatment 35 2.8  0.1 58 1.8  0.1 26 1.8  0.1
CuSO4 treatment 35 3.6  0.2** 99 1.9  0.0 37 2.1  0.1**
** p < 0.01.
IHC: hair bundles of the inner hair cells; OHC: hair bundles of the outer hair cells,
StrMC: strial marginal cells.
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ized by a bright signal and disturbed weak speciﬁc ﬂuorescence
signals, such as from TRITC conjugation.
Amphiphilic block copolymers have been shown to self-
assemble into polymersomes in an aqueous environment
(Letchford and Burt, 2007). Polymersomes are a class of vesicles,
nano-sized spheres that encapsulate an aqueous solution. They
have potential to act as drug delivery vehicles as they can carry
therapeutic agents and their surfaces can also be modiﬁed with
tissue-speciﬁc targeting moieties. In addition, small molecular
weight hydrophobic molecules can be incorporated into the
membrane (Ghoroghchian et al., 2007) and hydrophilic molecules
can be encapsulated in the aqueous core (Lomas et al., 2007). The
polymersome surface can be functionalized with groups that
promote cellular uptake (Christian et al., 2007) or target speciﬁc celltypes. These properties result in prolonged circulation times of the
polymersome within the body. Furthermore, CuSO4 treatment
eliminated the autoﬂuorescence in the inner ear, whereas the
signal from DiI was absolutely preserved. The ﬂuorescence signal of
Table 2
Fluorescent signal changes of TRITC-phalloidin binding in the cochlear cell pop-
ulations induced by CuSO4.
Groups IHC OHC StrMC
n Means  SEM n Means  SEM n Means  SEM
No treatment 22 4.9  0.4 51 3.0  0.1 32 3.4  0.1
CuSO4 treatment 39 5.5  0.3 79 3.0  0.1 43 3.0  0.1**
** p < 0.01.
IHC: hair bundles of the inner hair cells; OHC: hair bundles of the outer hair cells,
StrMC: strial marginal cells.
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encapsulated in the PEG-PCL polymersome nanoparticles and the
hydrophobic membrane of the nanoparticle prevented the passage
of CuSO4 into the core to react with the DiI tag. Similar mechanisms
may operate in other types of nanoparticles, such as the lipidic core
nanocapsules that encapsulate Nile red in the hydrophobic core
(Scheper et al., 2009; Zou et al., 2008). The method presented
herein greatly increased the speciﬁcity of nanoparticle detection in
the inner ear without compromising sensitivity.
Internalization of PEG-PCL polymersomes in live NIH3T3 cells
but not pre-ﬁxed cells proved that potential contamination of free
nanoparticles did not disturb the observation of internalization in
the inner ear cell populations since the dissection was performed
after ﬁxation with 4% PFA. PEG-PCL polymersomes were observed
in mesothelial cells of the scala tympani and vestibuli, capillaries of
the stria vascularis, spiral ligament ﬁbrocytes and spiral ganglion
region after 5 days transtympanic injection (Fig. 5). The potential
routes for PEG-PCL to access the spiral ganglion cell region after
intratympanic delivery is that the nanoparticles diffuse from the
scala perilymph to the “perimodiolar lymph” via the porous mod-
iolar wall of the scala tympani and scala vestibuli (Rask-Andersen
et al., 2006; Zou et al., 2008, 2009a,b, 2010). Distribution of PEG-
PCL in the stria vasculature may take the passage of trans-spiral
ligament diffusion (Zou et al., 2005, 2010). The details will be
investigated in the near future. However, PEG-PCL polymersomes
were not detected in the cells facing endolymph, such as IHCs,
OHCs, supporting cells of Corti’s organ, and stria marginal cells.
These results indicate poor transport of PEG-PCL polymersomes
into endolymph.
In the TRITC/FITC-labeled inner ear specimens, CuSO4 treatment
resulted in diverse signal intensity changes in the hair bundles of
IHC and OHC, and stria marginal cells according to quantiﬁcation.
The deviation in the ﬂuorescence signal intensity might have been
artiﬁcially generated during sampling, potentially due to different
focus planes under the confocal microscope or the region selection
for quantiﬁcation. However, the treatment greatly preserved the
labeling abilities of the ﬂuorescence signals, including the binding
of F-actin and the antibody, which have both been employed to
identify the cellular populations of the inner ear during the
Nanoear study with whole mounting techniques (Scheper et al.,
2009; Zou et al., 2008). Although the ﬂuorescence of FITC-conju-
gated phalloidin was greatly reduced by CuSO4 treatment, the
visualization of inner ear cells labeled by FITC-conjugated phalloi-
din was not compromised.
Heavy-metal ion treatment, including CuSO4, signiﬁcantly
decreases the ﬂuorescence intensity of extracted lipofuscin
components (Kikugawa et al., 1997). Metals in close proximity to
chromophores are known to quench ﬂuorescence in a distance
dependent fashion (Richmond et al., 2000). Cupric ionwas reported
to quench ﬂuorescence of DsRed (a bright red ﬂuorescent protein),
eGFP, and ﬂuorescent dyes entrapped in nanoparticles by binding
to amino acids close to the chromophores (Eli and Chakrabartty,
2006; Richmond et al., 2000; Gouanvé et al., 2007). When theemission spectra of chromophores (donor) are overlapped with the
absorption spectrum of cupric ion (accepter), energy transfer from
the donor to the accepter would happen. Cupric ion absorbs the
energy at emission wavelength of the donor without re-emitting
the energy ﬂuorescently resulting in ﬂuorescent quenching
(Gouanvé et al., 2007). Yellow ﬂuorescent components in lipofuscin
are composed of proteinaceousmaterial (Kikugawa et al.,1997). A2E
(2-[2,6-dimethyl-8-(2,6,6-trimethyl-1-cyclohexen-1-yl)-1E,3E,5E,-
7E-octatetraenyl]-1-(2-hydroxyethyl)-4-[4-methyl-6-(2,6,6-trime-
thyl-1-cyclohexen-1-yl)-1E,3E,5E-hexatrienyl]-pyridinium), an
isomer of a pyridinium bis-retinoid, dominates the red edge of the
emission spectrum of lipofuscin (Haralampus-Grynaviski et al.,
2003). We suspect that the mechanism of CuSO4 treatment to
quench autoﬂuorescence in the rat inner ear is through binding to
amino acids close to A2E and induce energy transfer. The ﬂuores-
cence of TRITC-conjugated phalloidin and DiI-tagged PEG-PCL pol-
ymersomes preserved by CuSO4 treatment might be caused by the
absence of binding site or an inefﬁcient remote binding site in the
agents. Therefore, the speciﬁc ﬂuorescent signal was distinguished
from the autoﬂuorescence after CuSO4 treatment.
In conclusion, visualization of ﬂuorescently tagged nano-
particles in the inner ear was greatly improved by CuSO4 treatment,
which eliminated autoﬂuorescence in the inner ear cell populations
while absolutely preserving the speciﬁc tag. The ability to identify
the inner ear cell populations using ﬂuorophore-conjugated
molecular probes was not comprised by CuSO4 treatment. This
method can be applied in studies of inner ear histology involving
ﬂuorescence techniques, such as the Nanoear project.Acknowledgements
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Comparison of the distribution pattern of PEG-b-PCL polymersomes
delivered into the rat inner ear via different methods
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Abstract
Conclusion: Cochleostomy is the most efﬁcient approach in delivering PEG-b-PCL polymersomes (PMs) to the inner ear. PMs
can be delivered to the vestibule by transtympanic injection or cochleostomy. Objective: To evaluate the efﬁciency of delivering
PEG-b-PCL PMs into the inner ear using different approaches. Methods: The PEG-b-PCL PMs were administered either by
sustained topical round window membrane (RWM) delivery using gelatin sponge pledgets in combination with an osmotic
pump, transtympanic injection, or cochleostomy. The distribution of the PMs in the inner ear was observed by confocal
microscopy using either whole mount specimens or cryosections. Results: Cochleostomy resulted in distribution of the PMs in
the spiral ligament (SL), mesothelial cells beneath the organ of Corti, supporting cells in the organ of Corti, and spiral ganglion
cells (SGCs). Transtympanic injection induced uptake of the PMs in the SL and mesothelial cells beneath the organ of Corti.
Topical administration showed distribution of the PMs only in the SL. In the vestibulum, transtympanic injection and
cochleostomy induced more distribution of the PMs than did topical RWM delivery (p < 0.05, Kruskal-Wallis test).
Keywords: Drug delivery, nanocarrier, imaging, animal
Introduction
Due to their targetability towards speciﬁc cell types,
biocompatibility, and versatility in carrying payloads
of different therapeutic agents, polymersomes (PMs)
have potential as drug delivery vectors for the treat-
ment of sensorineural hearing loss. PMs are vesicle-
like nanoparticles formed from synthetic amphiphilic
block copolymers such as poly(e-caprolactone)-block-
poly(ethylene glycol) (PEG-b-PCL) [1]. PMs have
been previously investigated as delivery vehicles of
therapeutic agents to the inner ear [2–4]. In in vitro
cultures, the uptake of PMs into spiral ganglion
neurons and glial cells was observed after periods
of 24 h with no indication of toxicity [3]. In cochlea
explants they displayed increased afﬁnity for spiral
ganglion cells (SGCs) when labelled with a short
peptide sequence that speciﬁcally binds to the tyrosine
kinase B (TrkB) receptor [4].
In the clinic, several techniques including transtym-
panic injection, topical round window membrane
(RWM) permeation, and a catheter installed through
the eustachian tube [5–7] are used for the transtympa-
nic administration of therapeutic agents. We have pre-
viously reported that PEG-b-PCL PMs delivered by
transtympanic injection passed the middle-inner ear
barriers and were distributed within the cochlea and
vestibulum [2]. As investigations have begun to eluci-
date the mechanisms and pharmacokinetics of the
topical application ofmedication destined for the inner
ear, newer strategies of delivery of therapeutics directly
to the inner ear are beginning to emerge.These include
modiﬁcations to existing cochlear implant technolo-
gies, osmotic pumps, and trans-RWM injection [8].
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More recently, the micro-cannula portion of the drug
deliverydevicehasbeenmodiﬁed topermit longerdrug
infusion times, as well as bolus dosing (such as for viral
vector delivery) [9]. In this study, the distribution
patterns of PEG-b-PCL PMs within the inner ear after
intracochlear delivery using an osmotic pump were
compared to those observed after transtympanic
administration by transtympanic injection and topical
RWM permeation.
Material and methods
Manufacturing and characterization of PMs
NH2-PEG5.8K-b-PCL19K (60 mg) was dissolved in
2 ml anhydrous N, N-dimethylformamide (DMF,
Sigma-Aldrich, UK). 4-Nitrophenyl-iodoacetate
(10 mg, Sigma-Aldrich) was added and the reaction
mixture was stirred for 4 h. Diethyl ether (50 ml,
Polymer Source Inc., Canada) was added and the
solution was left overnight; the resulting precipitate
was ﬁltered and washed with diethyl ether to give
iodoacetate-PEG5.8K-b-PCL19K (Polymer Source
Inc.) functionalized polymer (45 mg, 75% yield).
Then 15 mg of the solid was dissolved into DMF
(1 ml) to give a pale yellow solution that turned clear
when cystine terminated peptide (1 mg) was added.
The reaction mixture was stirred overnight, concen-
trated in vacuo, and used crude in nanoparticle
preparation.
The preparation of PEG-b-PCL PMs has been
reported previously [4]. Brieﬂy, 1,1¢-dioctadecyl-
3,3,3'3¢-tetramethylindocarbocyanine perchlorate
(DiI, Invitrogen, UK) was dissolved in DMF at a
concentration of 0.1 mg/ml. PEG5.8K-b-PCL19K
(6.0 mg) was dissolved in 0.4 ml of the DiI/DMF
solution (0.4 ml). The polymer solution was then
added dropwise (~1 drop every 8 s) to rapidly stirring
phosphate-buffered saline (PBS; 1.60 ml). The sam-
ple was dialyzed against PBS for 48 h with regular
changes of buffer solution. Dynamic light scattering
(DLS) was performed on a Coulter N4 Plus particle
sizer using N4 Plus version 1.10 software for data
analysis. The typical PM hydrodynamic diameter was
62.6 ± 9.2 nm. Before use in in vivo experiments the
PMs were sterile ﬁltered through a 0.2 mm cellulose
acetate syringe ﬁlter.
Animals
Five-month-old male Sprague Dawley rats with nor-
mal Preyer’s reﬂexes and weighing 350–450 g (sup-
plied by the experimental animal unit, University of
Tampere) were used in this study. Experiments were
performed in accordance with the directives of the
local ethics committee of the University of Tampere
(permission: LSLH-2006-4143/Ym23).
Three methods were used for delivery of PEG-b-
PCL PMs: transtympanic injection was applied to
four rats bilaterally, topical RWM delivery was used
in three rats bilaterally, and cochleostomy via osmotic
pump was performed in ﬁve rats unilaterally. Two
untreated rats were used as the control group.
All experimental procedures were performed under
general anesthesia by intraperitoneal injection of a
mixture of of medetomidine hydrochloride (0.8 mg/
kg) (Domitor, Orion, Finland) and ketamine hydro-
chloride (80 mg/kg) (Ketalar, Pﬁzer, UK). Three days
after treatment was started the animals were sacriﬁced
and the cochleae were harvested. They were either
wholemounted for confocalmicroscopy, ordecalciﬁed
with 10% EDTA and prepared for cryosectioning.
Administration of PMs to the inner ear
PM administration was performed under an operating
microscope. For transtympanic membrane injection,
40 ml of PMs were injected into the middle ear cavity
using 28-gauge needles. The injection volume was
deﬁned according to the literature report that the
average volume of an adult rat middle ear cavity is
42 ml [10]. During the procedure the animal eyes were
protected by Terra-Cortril-P (Pﬁzer).
For topical RWM delivery, the post-auricular
procedure was performed with an operating micro-
scope under aseptic conditions. The bulla was opened
with a 2 mm diameter burr. The stapedial artery was
exposed and the RWMwas identiﬁed above the artery.
An 8 mm3 gelatin sponge pledget saturated with PMs
was placed on the RWM. An osmotic pump ﬁlled with
100 ml of PMs was installed using a catheter (PE60,
Becton Dickinson Co.), in conjunction with a gelatin
sponge pledget that had been primed with the same
solution. For cochleostomy, the bony wall of the scala
tympani (ST) was opened by drilling with a 0.5 mm
burr.Themicro-osmotic pumpwasﬁlledwith100ml of
PMs and connected to a catheter (PE60 tube and
PE10 tube were linked by a PE30 tube; Becton Dick-
inson Co.), which was primed with the same solution.
The catheter tip (PE10) was inserted into the ST and
sealed with Histoacryl (B|BRAUN, Germany). The
catheter tube was ﬁxed on the bulla with phosphate
cement (Heraeus Kulzer GmbH, Germany) and
the osmotic pump was implanted subcutaneously in
the neck.
Atipamezole hydrochloride (2 mg/kg) was injected
intraperitoneally immediately after the operation to
accelerate the animals’ awakening from anesthesia.
Saline (2ml)wasadministered throughasubcutaneous
injection in the neck. Rimadyl (1.0 mg/kg, Pﬁzer) was
2 Y. Zhang et al.
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injected to relieve pain. Baytril (10 mg/kg; Orion,
Germany) was injected intraperitoneally once a day
to prevent potential infection.
Histological studies
Whole mount sample preparation. The bullae were ﬁxed
by cardiac perfusion with 4% paraformaldehyde
(Merck, Germany) (0.01 M PBS containing 0.6% v/v
heparin, pH 7.4, to remove the blood before ﬁxation).
The isolated cochleae were rinsed with water for 1min
to remove PMs remaining on the outer surface, then
stored in the ﬁxation solution for 2 h (whole mount
samples) or overnight (cryosection).
After washing with PBS, the basal turn, middle turn,
and apex (including the organ of Corti, spiral ligament
(SL) and modiolus) of the cochlea, the RWM, and the
utricle, the saccule and the ampullae of the vestibular
were isolated. The tectorial membrane was removed
under a stereo-microscope. The specimens were
stained with 4¢,6-diamidino-2-phenylindole (DAPI)
(10 mg/ml, Sigma-Aldrich) for 10 min at room tem-
perature in the dark. To diminish autoﬂuorescence, the
specimens were treated with 1 mM copper sulfate
(CuSO4) in 0.01 M ammonium acetate buffer (pH
5.0) [2]. After washing with PBS, the specimens were
placed on eight-well slides (Cel-Line/Thermoscienti-
ﬁc, USA) and mounted with Fluoromount (Sigma-
Aldrich) for confocal microscopy.
Cryosection preparation.After3weeksofdecalciﬁcation,
thecochleaewerewashedwithPBS, transferred to30%
sucrose for 24 h, and embedded with OCT compo-
nent (SakuraFinetek).Tissuewascut at30mmsections
using a cryostat (Leica CM3050S, Germany).
The cryoslides were washed with PBS for 5 min to
remove the OCT component, stained with DAPI
(10 mg/ml) for 10 min, washed with PBS, and
mounted with Fluoromount for confocal microscopy.
Confocal microscopy. Both the whole mount specimens
and the cryoslides were observed under a Nikon
inverted microscope Eclipse Ti installed with
ANDOR IQ. The excitation lasers were 568 nm
and 405 nm from an Andor Laser Combiner system.
The corresponding emission ﬁlters were 607/45 nm
(TRITC and DiI) and 450–465 nm (DAPI). For 3D
scanning, the interslice thickness was 0.5 mm.
Statistics
The ﬂuorescence of PMs on confocal microscopic
images of the RWM, SL, and vestibulum (utricle and
saccule) was measured using ImageJ 1.42q software
(Table I). The ﬂuorescence intensity was counted as
pixels with gray value ‡1 after subtracting the noise
signals. The ﬂuorescence intensities of the PMs deliv-
ered by the three methods were compared by Kruskal-
Wallis test using SPSS 11.5 software. A p value
< 0.05 was considered to be a signiﬁcant difference.
Results
Cochlear distribution of the PMs
The RWM distribution of the PMs was detected in all
animals, with signiﬁcantly lower ﬂuorescence signal in
the topical RWM group than in the other two groups
(p < 0.01, Kruskal-Wallis test; Figure 1). However,
the distribution pattern varied among different
groups; PMs were detected only in the outer epithelial
layer in the topical RWM and transtympanic injection
groups, but in all three layers in the cochleostomy
group (Figure 2A1 and A2, Figure 3A and E).
In theSL,PMsweredetected inall animals, as shown
by whole mount specimens (Figure 2). When the
Table I. Number of confocal microscopic images counted in the
ﬂuorescence intensity analysis.
Method RWM SL Vestibulum
TRWM 21 25 4
TTI 27 32 18
Cochleostomy 5 25 5
RWM, round window membrane; SL, spiral ligament; TRWM,
topical round window membrane; TTI, transtympanic injection.
Fluorescence location
RWM SL
**
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Figure 1. Comparison of the PEG-b-PCL polymersome ﬂuores-
cence signal intensities in the rat inner ear 3 days after adminis-
tration using different approaches. RWM, round window
membrane; SL, spiral ligament; TRWM, topical RWM delivery;
TTI, transtympanic injection. **p < 0.01,*p < 0.05 (Kruskal-Wallis
test).
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specimens were cryosectioned, PMs became visible
only in the type III SL ﬁbrocytes of animals receiving
cochleostomy administration (Figure 3C and G;
Figure 4). In the stria vascularis, PMs were found in
the lumens of the capillaries in the topical RWMgroup
and in the pericytes of the capillaries in the cochleost-
omy group (Figure 2C and M). In the organ of Corti,
PMs were observed in Hensen cells and Claudius cells
in the cochleostomygroup (Figure 3F).Distributionof
PMs in the spiral ganglion was also shown in the
cochleostomy group (Figure 2N and O, Figure 3H).
In the ST, PMs were detected in the mesothelial cells
beneath the organ of Corti in the transtympanic injec-
tion group and the cochleostomy group (Figure 2G
and L, Figure 3B and F).
Vestibular distribution of the PMs
Vestibular distribution of the PMs was detected in all
animals. Cochleostomy and transtympanic injection
induced a greater relative amount of PMs in the
utricle and semicircular canal (SCC) compared
with topical RWM administration. Relative distribu-
tions were obtained by measuring the ﬂuorescence
signal on confocal microscopic images of whole
mount specimens (p < 0.05, Kruskal-Wallis test,
Figures 1 and 4). Different PM distribution patterns
between the transtympanic injection and cochleost-
omy groups were observed on the cryoslides; these
differences were not seen using the whole mount
specimens. Post transtympanic injection, PMs were
detected in the endolymphatic and perilymphatic
space of the vestibulum, while post cochleostomy
they were detected in the utricular branch of the
vestibular nerve and mesothelial cells of the SCC,
facing the perilymph (Figure 5G–J).
Migration of the PMs to the contralateral cochlea
Post cochleostomy, PMs were detected in the con-
tralateral cochleae but this was not observed after
topical RWM or transtympanic injection. In the
RWM
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Figure 2. Panels A–O show the distribution of the PEG-b-PCL polymersomes in the rat inner ear 3 days after administration by different
methods demonstrated by whole mount specimen confocal microscopy. Panels P–T show the untreated specimens. A1 shows the epithelial
layer of the RWM. Arrows in A2 show the connective tissue layer of the RWM. Arrows in C, H, M, and R show the nuclei of the endothelial
cells of the capillaries in StrV. Red: polymersomes. *Spiral ganglion cells. B, G, L, and Q, cells lining ST beneath the organ of Corti. RWM,
round window membrane; SG, spiral ganglion; SL, spiral ligament; ST, scala tympani; StrV, stria vascularis; TRWM, topical RWM delivery;
TTI, transtympanic injection. Blue: DAPI. Scale bar = 10 mm.
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contralateral cochleae, the PMs were observed in the
mesothelial cells of ST in the ﬁrst turn, the epineu-
rium of the cochlear nerve in the modiolus, and in the
cochlear nerve in the internal meatus (Figure 6).
Discussion
There are two pathways for drugs to be transported
from the middle ear cavity into the inner ear in rats:
through the RWM to the perilymph in the ST or
through the annular ligament of the oval window to
the vestibular perilymph [11]. The RWM is a semi-
permeable membrane that prevents hazardous sub-
stances from entering the inner ear, but it also
prevents the effective passage of therapeutics. The
epithelial layer has tight junctions [12], whereas the
connective tissue layer and the endothelial layer are
loosely arranged. It is likely that the PMs pass through
the epithelial layer via a transcellular pathway, then
through the connective tissue layer and the endothelial
layer via an intercellular pathway [12]. The PMs were
detected in only the epithelial layer of the RWMwhen
RWM
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Figure 3. Distribution of the PEG-b-PCL polymersomes (PMs) in the rat inner ear 3 days after administration by different delivery methods, as
demonstrated by cryosection confocal microscopy. TTI induced the distribution of the PMs in the outer epithelium of the RWM, while
cochleostomy resulted in the distribution of the PMs in all three layers of the membrane. Arrows in (B) and (F) highlight the distribution of the
PMs in the mesothelial cells of the ST beneath the organ of Corti. The arrowhead in (F) shows PMs in the Claudius cells and the Hensen cells.
(G) Distribution of the PMs in the type III spiral ligament ﬁbrocytes. (H) PMs in spiral ganglion glial cells. RWM, round window membrane;
SG, spiral ganglion; SL, spiral ligament; SM, scala media; ST, scala tympani; TTI, transtympanic injection; 1, outer epithelial layer of the
RWM; 2, connective tissue layer of the RWM; 3, inner endothelial layer of the RWM. Red: PMs. Blue: DAPI. Gray in (F) and (G): bright ﬁeld.
*Nuclei of type I SGCs. Scale bar in A, C, and E–G = 50 mm. Scale bar in B, D, and H = 20 mm.
ST
RWM
SL
ST
RWM
SL
A B
Figure 4. Migration of the polymersomes (PMs) from the scala tympani (ST) to the round window membrane (RWM) and spiral ligament
(SL) after cochleostomy administration as shown by cryosection confocal microscopy. Arrowheads show the mesothelium of the ST; arrows
show a blood vessel in the type III spiral ligament ﬁbrocytes region. (A)Merged images from the red channel, blue channel, and bright ﬁeld. (B)
Enlarged window of the red channel in (A) allows visualization of the PMs. Red: PMs. Blue: DAPI. Scale bar = 100 mm.
Delivery methods and distribution of polymersomes 5
A
ct
a 
O
to
la
ry
ng
ol
 D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
Ta
m
pe
re
 U
ni
ve
rs
ity
 o
n 
10
/1
2/
11
Fo
r p
er
so
na
l u
se
 o
nl
y.
delivered by topical RWMdelivery and transtympanic
injection; however, they were detected in all three
layers of the RWM when administered via cochleost-
omy. This ﬁnding suggests that PMs were taken up by
the endothelial cells while diffusing through loose
intercellular gaps of the endothelium to the connective
tissue core. The PMs were then internalized by the
epithelial cells after entering into the cochlear
perilymph. However, after topical RWM delivery
and transtympanic injection most of the PMs were
internalized by the epithelial layer of the RWM and
most of them failed to be transported to the connective
tissue layer and the endothelial layer of the RWM.
Variable transport efﬁcacy of different agents across
the RWM has been reported in the literature.
Trimethylphenylammonium (TMPA) passed the
TRWM TTI
A B C D
HGFE
I J K L
TTI
Cochleostomy
Cochleostomy
Endolymph
Utricle
Perilymph
Utricle Utricle
Endolymph
Perilymph
SCC
Untreated
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Figure 5. Vestibular distribution of the PEG-b-PCL polymersomes (PMs). Whole mount samples show the appearance of the PMs in the
utricle (A–C) as well as in the semicircular canal (SCC) (E–G) when delivered via TRWM (topical round window membrane), TTI
(transtympanic injection), and cochleostomy and the untreated specimens (D and H). Cryosections show the endolymphatic (I) and
perilymphatic (J) distributions of the PMs in the utricle after TTI delivery; the PMs were found in the utricular branch of the vestibular nerve
(K) and in the epithelial cells of SCC (L) after cochleostomy administration. Red: PMs. Blue: DAPI. Scale bar in A–F = 10 mm. Scale bar in
G–J = 100 mm.
A B C
SL
SM
ST
Figure 6. Appearance of the PEG-b-PCL polymersomes (PMs) in the contralateral cochlea after administration via cochleostomy. The PMs
were detected in the mesothelial cells of ST in the basal turn (A), perineurium of the cochlear nerve in the modiolus (arrows in B), and in the
internal meatus (C). SL, spiral ligament; SM, scala media; ST, scala tympani. Red: PMs. Blue: DAPI. Scale bar = 50 mm.
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RWM and was detected at 16.5% of the original
concentration in the ST of the basal turn 90 min after
RWM administration [13]. Proteins such as bacterial
endotoxins have shown poor passage through the
RWM; the concentration detected in the perilymph
was 0.01% of the original concentration when applied
by topical RWM delivery [14]. Topical RWM admin-
istration of nanocarriers carrying a payload of gadolin-
ium resulted in poor loading of the nanoparticles in the
rat inner ear as shown by in vivo magnetic resonance
imaging (MRI) [6]. However, transtympanic injection
of PEGylated liposome nanocarriers encapsulating
gadolinium-tetra-azacyclododecane-tetra-acetic acid
(Gd-DOTA) passed the RWM efﬁciently, as detected
by the Gd-DOTA signal in the inner ear using in
vivo MRI [11]. The variable efﬁcacy in crossing the
middle-inner ear barriers is likely dependent on the
different surface characteristics of the nanocarriers.
After transtympanic injection, more PMs were
detected in the vestibulum than in the cochlea, indi-
cating that the PMs entered the vestibulum through
the oval window [11]. A histological study in rats
demonstrated that the annular ligament across the
stapedio-vestibular joint is a porous structure com-
posed of ﬁbrillin, 36 kDa microﬁbril-associated
glycoprotein (MAGP-36), and hyaluronic acid, which
supports our MRI results [15]. Our serial human and
animal MRI studies constantly demonstrated greater
uptake of gadolinium in the vestibulum than in the ST
when administered to the middle ear cavity by differ-
ent means [6]. Recently, we showed that the oval
window is an effective pathway for transport of
Gd-DOTA from the middle ear to the vestibulum
and is more efﬁcient than the RWM [16].
Administration via cochleostomy displayed the
broadest distribution of PMs in the inner ear. The
organofCorti has a loose structure anddextran applied
to theperilymphof theSTgained access themajority of
cell types within the cochlea, as well as the nerve ﬁbers
in the peripheral processes of the spiral ganglion cells
[17]. Zou et al. have also hypothesized that lipid nano-
capsules may reach the spiral ganglion cells through a
‘nerve pathway’ from the Corti’s ﬂuid (inside the
Corti’s tunnel) [18]. A short-cut between the peri-
lymph and modiolus was also indicated by both elec-
tronmicroscopy studies on human cochlea and in vivo
MRI investigations in guinea pigs [19–21]. This short-
cutmay also be utilized as the PMsmigrate to the spiral
ganglion cells from the ST. Transportation of the PMs
from the ST to the scala vestibuli may be mediated by
either the SL or the modiolus [20]. Consequently, the
PMs are further distributed from the vestibule to the
scala vestibuli. Cochlear distribution of PMs was
mostly preserved using the whole mount histological
method, but signiﬁcantly decreased by cryosectioning.
It is likely that loosely deposited PMs in the intercel-
lular space were washed away during the cryosection-
ing procedure. This indicates that whole mount
method is a preferable method to demonstrate tissue
location of PMs in the cochlea. However, preparation
of samples using cryosectioning may provide addi-
tional information on the spatial location of PMs
restrained in the inner ear.
Our study contributes to the optimization of
PM-mediated inner ear drug delivery. Although trans-
tympanic injection of the PMs was not superior to
topical RWM application in terms of their delivery
into the cochlea, it was more efﬁcient in delivering
thePMs into the vestibulumthan topicalRWMadmin-
istration. However, both methods failed to distribute
the PMs into the spiral ganglion or the organ of Corti.
Among the evaluated delivery approaches, cochleost-
omy is the most promising method with which to
deliver the PMs into these locations. This supports
the development of new strategies for the delivery of
therapeutics directly to the inner ear using either mod-
iﬁcations to existing cochlear implant technologies or
osmotic pumps. This information is also relevant to
exploring trans-RWM injection of PMs.
The appearance of the PMs in the contralateral
cochlea and internal auditory canal may be mediated
by the cochlear aqueduct, which is located in the hook
region of the basal turn of the ST. This passage was
identiﬁed in an in vivo MRI study by Zou et al. in the
guinea pig, which showed that blockage of the cochlea
aqueduct prevented backﬂow of gadolinium from the
perilymph in the ST to the cerebrospinal ﬂuid (CSF)
[19].Communicationbetween theperilymphandCSF
may cause adverse effects in the brain and contralateral
cochlea during inner ear drug delivery. We expect that
the advanced nanocarriers (including PMs) equipped
with targeting moieties will ﬁne-tune the use of these
agents.
Conclusions
Cochleostomy is the most efﬁcient approach to deliv-
ery of PEG-b-PCL PMs to the cochlear cells and
vestibular cells. Transtympanic injection induced a
broader vestibular distribution of the PMs than the
topical RWM approach. Different inner ear drug
delivery approaches should be considered according
to the purpose of treatment.
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Abstract: Hearing loss is a major public health problem, and its treatment with traditional
therapy strategies is often unsuccessful due to limited drug access deep in the temporal bone.
Multifunctional nanoparticles that are targeted to specified cell populations, biodegradable,
traceable in vivo, and equipped with controlled drug/gene release may resolve this problem.
We developed lipid core nanocapsules (LNCs) with sizes below 50 nm. The aim of the present
study is to evaluate the ability of the LNCs to pass through the round window membrane and
reach inner ear targets. FITC was incorporated as a tag for the LNCs and Nile Red was
encapsulated inside the oily core to assess the integrity of the LNCs. The capability of LNCs to
pass through the round window membrane and the distribution of the LNCs inside the inner
ear were evaluated in rats via confocal microscopy in combination with image analysis using
ImageJ. After round window membrane administration, LNCs reached the spiral ganglion
cells, nerve fibers, and spiral ligament fibrocytes within 30 min. The paracellular pathway was
the main approach for LNC penetration of the round window membrane. LNCs can also reach
the vestibule, middle ear mucosa, and the adjacent artery. Nuclear localization was detected
in the spiral ganglion, though infrequently. These results suggest that LNCs are potential
vectors for drug delivery into the spiral ganglion cells, nerve fibers, hair cells, and spiral
ligament. ' 2008 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater 87B: 10–18, 2008
Keywords: nanoparticles; inner ear; drug delivery; neuron; biological barrier
INTRODUCTION
Hearing loss is a major public health problem that ranks
8th among common diseases in the EU. The traditional
treatment strategy for sensorineural hearing loss (SNHL)
has not been very successful. The human cochlea is deeply
buried in the temporal bone, and its access is limited by
membranous partitions. The blood supply derived from the
intracerebral vessels hampers any efforts for intravascular
treatment. Cochlear implantation (CI) bypasses the mem-
branous borders and provides direct contact with cochlear
partitions. Thus far, only electrical stimulation has been
used in hearing rehabilitation, and CI is a well-established
method for restoring severe or profound hearing loss. How-
ever, hearing performance after implantation is variable
due to several causes.1–4 A cure for SNHL would thus
depend on novel concepts such as successful gene or drug
delivery alone or in combination with CI.5
To achieve an ideal outcome with a minimum amount
of adverse effects, novel multifunctional nanoparticles
(MNPs) could be used. These must possess special charac-
teristics such as the ability to be targeted to speciﬁed cell
populations, as well as being biodegradable, traceable
in vivo, and equipped with controlled drug/gene release. In
clinical practice, a minimally invasive delivery approach is
desired. One such method is round window membrane per-
meation, which is an efﬁcient and minimally invasive
method of administering substances into the inner ear, as
has been proved in both animal and human studies.6,7 The
method is also feasible, as suggested by reports on gene
delivery through intact round window membranes and
expression in the cochlea.8,9 Reports from clinical observa-
tion of transtympanic steroid treatments for SNHL indicate
that the presence of a controlled sustained release of drug
into the inner ear can determine the outcome of patients.10–12
According to Praetorius et al., silica nanoparticles can
reach all cell populations of the inner ear upon delivery
onto the round window membrane.13 Hitherto, silica nano-
Correspondence to: J. Zou (e-mail: Jing.Zou@uta.ﬁ)
Contract grant sponsor: EU project Nanoear; Grant numbers: NMP4-CT-2006-
026556
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particles face problems in loading and releasing drugs in a
controlled fashion.
Lipid core nanocapsule (LNC) possesses sustained
release property for amiodarone.14 For this study, the LNC
was further modiﬁed to be made visible in tissues by incor-
porating FITC into the LNC to serve as a tag. Nile Red
was encapsulated inside the oily core to assess the integrity
of the LNC in vivo. If FITC and Nile Red co-localize
inside the tissues, the LNC must be intact; otherwise it is
considered degraded. The aim of the present work is to
demonstrate that the LNC can permeate the round window
membrane, pass the cochlear partitions, and address inner
ear cell populations.
MATERIALS AND METHODS
Materials and Animals
Materials for LNC manufacturing include: the lipophilic
Labrafac_WL 1349 (caprylic-capric acid triglycerides;
European Pharmacopeia, IVth, 2002) which was kindly
provided by Gattefosse´ S.A. (Saint-Priest, France), Lipoı¨d
S75-3 (soybean lecithin with 69% of phosphatidylcholine),
and Solutol HS 15 (mixture of free polyethylene glycol
660 and polyethylene glycol 660 hydroxystearate, European
Pharmacopeia, IVth, 2002), which were gifts from Lipoı¨d
Gmbh (Ludwigshafen, Germany) and BASF (Ludwig-
shafen, Germany), respectively. Because of the complex
composition of each product, the brand names will be used
in the following text. NaCl was obtained from Prolabo
(Fontenay-sous-Bois, France). Water was obtained from a
Milli RO System (Millipore, Paris, France). Fluorescein-5-
isothiocyanate (FITC) was purchased from Fluoresce´ine
IsoThioCyanate (France), Nile Red and 3,30-Dioctadecylox-
acarbovyanine perchlorate (DiO) were purchased from
Sigma-Aldrich (USA), and Rhodamine B was purchased
from ChemExper Inc. (Belgium). 1,2-Distearoyl-sn-Glycero-
3-Phosphoethanolamine-N-[Amino(PolyethyleneGlycol)2000]
(called DSPE-PEG2000-amino in the text) was furnished by
Avanti1 Polar Lipids, Inc (Alabaster, USA).
Materials for animal testing included elastase (Sigma-
Aldrich, USA), collagenase type I (Sigma-Aldrich, USA),
trypsin (Sigma-Aldrich, USA), fetal calf serum (Invitrogen,
USA), paraformaldehyde (Sigma-Aldrich, USA), FITC-la-
beled phalloidin (Sigma-Aldrich, USA), rabbit anti-neuroﬁl-
ament 200 polyclonal antibody (Sigma-Aldrich, USA),
FITC-labeled goat anti-rabbit IgG (Sigma-Aldrich, USA),
40,6-Diamidino-2-phenylindole (DAPI) (Sigma-Aldrich,
USA), Gel MountTM Aqueous Mounting Medium (Sigma-
Aldrich, USA), O.C.T. (Electron Microscopy Sciences,
USA), medetomidine hydrochloride (Orion, Finland), atipa-
mezole hydrochloride (Orion, Finland), Ketamine (Pﬁzer,
USA), L-Polamivet (Intervet, Finland), and oﬂoxacin
(Aventis Pharmacy, Finland).
Nine male Sprague-Dawley rats with normal Pryer’s
reﬂex (supplied by the experimental animal unit, University
of Tampere) were used in the study in accordance with the
local ethics committee of University of Tampere standards
(permission no: 985/2003). They were divided into ﬁve
groups according to their time points (Table 1). All animal
experiments were approved by the Ethical Committee of
the University of Tampere. Animal care and experimental
procedures were conducted in accordance with European
legislation.
LNC Preparation
The ﬁrst step of the formulation was an emulsion consist-
ing of Labrafac1 WL 1349, an oil made of capric and ca-
prylic acid triglycerides (average molecular weight of 512);
Lipoid1 S75-3, a soybean lecithin made of 69% phosphati-
dylcholine and other phospholipids; Solutol1 HS 15,
another surfactant; a mixture of polyethylene glycol 660
hydroxystearate (C18E15); and free polyethylene glycol
660. The optimal amounts of ingredients for preparation
of 50 nm LNC were: Labrafac1 (1.028 g), Lipoı¨d1 (0.075
g), Solutol1 (0.846 g), NaCl (0.089 g) and pure water
(2.962 g). This mixture was prepared under magnetic stir-
ring at room temperature to obtain an emulsion of oil in
water. After progressive heating at a rate of 48C/min under
magnetic stirring, we observed a short interval of transpar-
ency at temperatures close to 708C, and the inverted phase
(water droplets in oil) was obtained at 858C. Then, three
cycles of cooling and heating were applied between 858C
and 608C at the same rate of 48C/min (near the phase
inversion zone), and ﬁnally a fast dilution in cold water at
a temperature close to 08C produced a suspension of nano-
capsules.15,16
DSPE-PEG2000-Amino Postinsertion
LNCs were incubated for 90 min with an aqueous micellar
solution of DSPE-PEG-amino at 608C. The suspension was
vortexed every 15 min and then quenched in an ice bath
for 1 min. The ﬁnal DSPE-PEG concentration corresponded
to 6 mol % of total surface molecules (i.e., Solutol and
Lipoı¨d).17
TABLE 1. Grouping of the Ear for Round Window Membrane
Delivery of LNC
Groupsa
Side of
the Ear
Number of
Animals
Number of
the Ear
30 min Left side 5 5
60 min Right side 4
180 min Right side 1
1 dayb Both side 2 4
7 dayb Both side 2 4
a The time between sampling and the administration of LNC.
b Left ear with transient administration of LCN (30 min), right side with constant
delivery.
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Nile Red and DiO Encapsulation
A volume of 55 lL (0.18 lmol) of a Nile Red in ethanol
solution (1 mg/mL) was added to the LNC emulsion, just
before diluting the system with cold water. The Nile Red
was totally encapsulated in the oily core, with the ﬁnal
concentration of 174 lmol/L. For DiO encapsulation, Nile
Red was replaced by 153 lg DiO and the ﬁnal concentra-
tion was 174 lmol/L.
FITC and Rhodamine B Labeling
After the postinsertion process, 2 mg of FITC isothiocyanate
(5.13 lmol) was added to 2.95 mL of LNC suspension and
the pH was increased to 10 by adding of a few drops of
0.1M Na3PO4 solution. The sample was protected from light
and placed in a water bath under magnetic stirring at 358C
for 45 min. After the sample was cooled in an ice bath for 3
min in order to stop the reaction, size exclusion chromatogra-
phy on a sephadex G-15 column was performed to separate
free FITC from labelled LNCs. Optical density (FITC detec-
tion) as well as turbidity at 680 nm (LNC detection) was
measured for each fraction [Figure 1(A)]. Fractions corre-
sponding to the FITC labeled LNCs were analysed by
dynamic light scattering. Electrokinetic measurements were
performed at a constant conductivity (0.03 ls cm21). These
measurements indicated a hydrodynamic diameter of 52 6 5
nm and a zeta potential of 255 6 7 mV (for non labelled
LNCs we obtained 27 6 3 mV) [Figure 1(B)]. Only frac-
tions with a polydispersity index lower than 0.2 were pooled
and used for animal testing [Figure 1(C)]. For Rhodamine B
labeling, FITC was replaced by 2 mg Rhodamine B.
Round Window Membrane Delivery of LNCs
Animals were fully anesthetized with medetomidine hydro-
chloride (0.5 mg/kg) and ketamine (75 mg/kg). The opera-
tion was performed under sterile conditions. After local
analgesia with lidocaine, a retro-auricular incision was used
to expose the left bulla. A hole was drilled on the bulla
with a 2 mm diameter burr. After visualizing the stapes ar-
tery, the round window membrane was identiﬁed above the
artery. A small piece of gelfoam (around 8 mm3) was satu-
rated with LNC and placed on the round window mem-
brane (LNC concentration: 20.5 g/L, stored at 48C for 3
months). The ears were divided into ﬁve groups of 30 min,
60 min, 180 min, 1 day, and 7 days according to the sam-
pling time post-LNC administration (Table 1). For the 1
day and 7 day groups, gelfoam was placed on the left ear
for 30 min and then removed, whereas gelfoam was placed
on the right ear constantly until the end of the experiment.
The hole on the bulla was sealed with muscle and the
wound was sutured in the 1 day and 7 day groups. Atipa-
mezole hydrochloride (2 mg/kg) was injected i.p. immedi-
ately after the operation to accelerate recovery from
anaesthesia of the animals. Saline (2 mL) was administered
through subcutaneous injection on the neck. L-Polamivet
(0.4 mL/kg) was injected b.i.d. to relieve the pain. Oﬂoxa-
cin (20 mg/kg) was injected b.i.d. in the 1 day and 7 day
groups after operation.
Whole Mount Sample Preparation
Following i.p. injection of pentobarbital (60 mg/kg), 2–3
mL of air was cardio injected to sacriﬁce the animals. The
bulla was removed and ﬁxed in 4% paraformaldehyde for 1
h. The cochlea was thoroughly washed with tap water for
30 s and then opened by breaking the bony wall under a
stero-microscope, and washed again with PBS for 2 3 5
min. The bulla was counter stained with DAPI (10 lg/mL)
for 10 min, and further washed three times for 5 min each
with PBS in a dark room. The middle ear mucosa, stapes
artery, round window membrane, lateral wall, and modiolus
from the basal turn, cochlear nerve, and ampulla of the
semi-circular cannel were taken under a stereo-microscope,
placed on glass slide, and mounted with Gel MountTM
Aqueous Mounting Medium for confocal microscopy.
Cochlear Cell Isolation
To conﬁrm the cellular internalization of LNCs, one small
piece of tissue, each from the cochlear modiolus and lateral
wall (ﬁxed with 4% paraformaldehyde), was treated with
elastase (1 mg/mL), collagenase type I (1 mg/mL) and
trypsin (0.5 mg/mL) at 378C for 15 min. The enzymes
were inactivated through incubation with DMEM contain-
ing 5% fetal calf serum at room temperature for 5 min.
The isolated cells were placed on glass slides and mounted
with Gel MountTM Aqueous Mounting Medium for confo-
cal microscopy.
Cryosectioning
For clariﬁcation of the cellular population in the lateral
wall, one piece of the ﬁxed lateral wall was embedded with
O.C.T., sectioned by a cryostat (Leica CM3050S, Germany)
in 5-lm sections, and mounted with Gel MountTM Aqueous
Mounting Medium.
Cellular Speciﬁc Staining
To conﬁrm the cell population of the cochlea with regard
to the LNCs distribution, immunoﬂuorescent staining was
applied to visualize neuroﬁlament in the cochlear nerve
tissue, and FITC-labeled phalloidin was used to probe F-
actin in the organ of Corti and lateral wall. After ﬁxation
and washing as stated above, permeation with 0.3% Triton
X-100 PBS for 5 min, and washing again with PBS, lateral
wall soft tissue was isolated from the bone and incubated
in FITC-labeled phalloidin (50 lg/mL) for 40 min and then
in DAPI for 10 min. After washing with PBS for 2 3 5
min, stria vascularis was isolated from the spiral ligament
and both tissues were mounted as stated above. After incu-
bation with preimmunized goat serum (1:20), the modiolus
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including basilar membrane was incubated with rabbit anti-
neuroﬁlament 200 polyclonal antibody (1:1000) overnight
at 48C, washed with PBS containing 0.2% Tween 20 (PBS-
T), and counterstained with DAPI for 10 min; the basilar
membrane, together with bony spiral laminar, was isolated
from the modiolus and mounted as stated above.
Confocal Microscopy
The whole mount samples and cryosectioned slices were
observed under an Olympus microscope IX70 installed
with ANDOR IQ. The excitation ﬁlters were 488 nm (blue
excitation) and 568 nm (green excitation), with an Ar-Kr
laser as the excitation source. The corresponding emission
ﬁlters were 525/50 (FITC and DiO) and 607/45 (Nile Red
and Rhodamine B). DAPI was excited with a 340–380 nm
ﬁlter and detected using a 500 LP ﬁlter. For 3D scanning,
the inter slice thickness was 0.5 lm. The image data was
rendered with ImageJ 1.32j software.
RESULTS
Thirty minutes after administration of the LNC in the tym-
panic cavity on the round window membrane, abundant LNCs
were found in the spiral ganglion cells [Figure 2(A–C)].
LNCs also attached to the outer surface of nerve ﬁbers
of the spiral ganglion; this was conﬁrmed by neuroﬁlament
staining [Fig. 2(D)]. Nuclear localization was detected in the
spiral ganglion, though infrequently [Figure 2(D)]. However,
the spiral ganglion distribution intensity of LNCs after thor-
ough treatment including washing with surfactant (Tween-
20) during neuroﬁlament staining was much lower than
without the staining. LNCs were also visible in the inner
hair cells and pillar cells as conﬁrmed by F-actin staining
[Figure 2(E–G)]. Again as a result of staining for neuroﬁla-
ment, LNCs were totally invisible in the organ of Corti
[Figure 2(H)]. The distribution of LNCs in the lateral wall
was found in both the spiral ligament and stria vascularis
[Figure 2(I–L)]. The surface appearance of marginal cells of
the stria vascularis after F-action staining showed that the
intercellular complexes corresponded to the scanning elec-
tron microscopy report.18 LNCs were frequently detected in
the intercellular junction area of the marginal cells [Figure
2(K)]. Visualization of LNCs in a single cell isolated from
the lateral wall conﬁrmed the internalization of LNCs
[Figure 2(N)]. After long incubations with various solutions
and many washes during F-actin staining, LNCs disappeared
from the spiral ligament while still remaining visible in the
stria vascularis. There was also a gradient distribution in the
stria vascularis in that more LNCs appeared in the second
turn than the basal turn [Figure 2(K,L)]. The amount of
LNCs in the cochlea as shown by F-actin staining was much
lower than that in the cochlea without the speciﬁc staining.
These further proved that long time processing swept the
extracellular LNC away and the internalization occurred
mainly in the stria vascularis rather than the spiral ligament.
There was also uptake of LNCs in the stapedial artery,
which has been shown to pass by the round window in rats
[Figure 2(M)]. The loss of co-localization of Nile Red and
FITC indicates the degradation of some LNCs.
One hour postround window membrane delivery, LNCs
appeared in the tunnel ﬁbers in the organ of Corti [Fig
3(A)]. LNCs went further distally and were also detectable
in the outer hair cells [Figure 3(B,C)]. The internalization
of LNCs in the cochlear hair cells was conﬁrmed by iso-
lated single cell imaging [Figure 3(G–I)]. LNCs inside the
spiral ligament spread to the type V ﬁbrocytes, which is
adjacent to the perilymph of the scala vestibule [Figure
3(D,E)]. LNCs were also found in the spiral prominence
and outer sulcus cells [Figure 3(F)].
The possibility of a paracellular pathway for penetration
of LNCs through the round window membrane was indicated
by the different behavior of LNCs 24 h after transient deliv-
ery (LNCs were placed on the round window membrane for
30 min and then removed) and constant administration
(LNCs were constantly placed on the round window mem-
Figure 1. Characterization of FITC labeled LNCs. A: Separation of
free FITC from labeled LNCs with Sephadex G15. The ﬁrst peak
showed absorbance at both 490 nm and 680 nm, indicating FITC-
conjugated LNCs with encapsulated Nile Red. The second peak
showed only absorbance at 490 nm, indicating free FITC. B: LNC
size for each fraction after chromatography on Sephadex G-15. C:
Polydispersity index for each fraction after chromatography on
Sephadex G-15. [Color ﬁgure can be viewed in the online issue,
which is available at www.interscience.wiley.com.]
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brane until the end of the experiment). The abundant accu-
mulation of LNCs in the round window membrane including
the matrix and cytoplasm was detected on the constant deliv-
ery side [Figure 4(A)], while only a few LNCs were visible
inside the cytoplasm after transient delivery [Figure 4(B)].
Concomitantly, more LNCs reached the hair cells which
were continuous with the tunnel ﬁbers [Figure 5(A–D)]. The
number of LNCs in the spiral ganglion cells and spiral liga-
ment also increased. Most LNCs accumulated around (but
did not enter) the nuclei, although spiral ganglion cells had
the quickest uptake during the ﬁrst 30 min [Figures 2(A–C)
and 5(E–H)]. LNCs were also detected in the vestibule,
including the semicircular canal and macula utricle.
LNCs remained in the spiral ganglion, including the
neuron and nerve ﬁbers, organ of Corti, and lateral wall
seven days after round window membrane delivery (Fig 6).
Some of the Nile Red and FITC lost co-localization, which
indicated degradation of the LNCs.
DISCUSSION
In the present study, we demonstrate that LNCs pass the
round window membrane, penetrate the cochlear membra-
nous partitions, and are incorporated into various cell types
within the cochlea. The pathway that the nanoparticles use in
passing through the round window membrane could be either
via endocytosis or through a nonendocytotic pathway such as
those seen in nonviral gene delivery.19 Our data showed that
there was abundant accumulation of LNCs in the round win-
dow membrane, including the matrix and cytoplasm on the
side of constant delivery [Figure 4(A)], while few LNCs
were visible inside the cytoplasm after transient delivery. We
suppose that the nonendocytosis pathway, the so-called ‘‘par-
acellular pathway,’’ seems to be the main channel for the
LNCs to penetrate the round window membrane. The rapid
incorporation of LNCs in the spiral ganglion cells, organ of
Corti, and lateral wall upon delivery to the round window
membrane can be explained by a paracellular pathway.
The rapid accumulation of LNCs in the spiral ganglion
cells indicated that the most likely pathway is directly
through the porous modiolar wall of the scala tympani.20
The uptake of LNCs in the tunnel ﬁbers may originate
from either the spiral ganglion or the basilar membrane.
The inner and outer hair cells are innervated by afferent
nerve ﬁbers that come from spiral ganglion cells and effer-
ent nerve ﬁbers that come from the superior olivary com-
plex. Approximately 90% of the afferent nerve ﬁbers end
in synaptic boutons on the inner hair cell bodies (the inner
Figure 2. Localization of LNCs in different cell populations in the cochlea 30 min post-round win-
dow membrane administration. There were abundant nanoparticles in the spiral ganglion cells as
shown by whole mount confocal microscopy (A. Nile Red signal; B. FITC signal; C. merged signal).
Neuroﬁlament of the spiral ganglion cell was seen with a speciﬁc antibody using a whole mounting
method (arrow), nuclear localization of LNCs was detected, though infrequently (broad arrow) (D).
LNCs reached the inner hair cells as shown by three-dimensional imaging using F-actin staining
(arrow) (E, front view; F, lateral view). There was also uptake in the pillar cells as shown by F-actin
staining (arrow) (G). However, after neuroﬁlament staining (arrow), LNCs were invisible in the organ
of Corti (H). There was also a distribution of LNCs in the lateral wall (I–K). Spiral ligament localiza-
tion was conﬁrmed by cryosection (arrow) (J); localization in the second turn of stria vascularis,
especially intercellular junction site (arrow), was conﬁrmed by F-actin staining (K, whole mount).
LNCs were not visible in the basal turn after staining for F-actin (L, whole mount). Coagulated
LNCs were detected in the stapes artery (M, whole mount). Only FITC was visible in some places,
indicating the degradation of LNCs (arrow). The single cell image proved that the nanoparticles
entered the cells (N). Scale bar 5 8.5 lm.
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Figure 3. Nanoparticles diffused further 1 h after administration. LNCs were visible in the tunnel
ﬁbers (arrow) (A), pillar cells (PC) and the outer hair cells (OHC) in the organ of Corti (arrow) (B, C),
and lateral wall (D–F). The cell population was conﬁrmed by F-actin staining (C). LNCs were primar-
ily located in the matrix of the lateral wall (arrow) (D). The spiral ligament ﬁbrocytes type V, which
are adjacent to the scala vestibuli, showed uptake of nanoparticles (arrow) as demonstrated by
cryosection (E). LNCs also diffused to the spiral prominence (arrow) as showed by cryosection (F).
The uptake of nanoparticles in the inner hair cells was further demonstrated by isolated single cell
imaging (G, Nile Red signal; H, FITC signal; I, merged signal). IHC, inner hair cells; the numbers 1,
2, and 3 refer to the outer hair cells row 1, row 2, and row 3. Scale bar 5 8.5 lm. [Color ﬁgure can
be viewed in the online issue, which is available at www.interscience.wiley.com.]
Figure 4. Round window membrane permeation of LNCs. Abundant LNCs were present throughout
the round window membrane during constant 24 h administration (A). Only a few particles were de-
tectable 24 h after transient delivery (LNCs were placed on the round window membrane for 30
min) (B). Scale bar 5 6.8 lm. [Color ﬁgure can be viewed in the online issue, which is available at
www.interscience.wiley.com.]
radial bundles). Only 10% of the afferent nerve ﬁbers in-
nervate the outer hair cells (the tunnel radial bundles, tun-
nel crossing bundles).21 Efferent innervation of auditory
hair cells is provided by the ﬁbers of the lateral olivo-
cochlear bundle to inner hair cells and the medial olivo-
cochlear bundle (also referred to as efferent tunnel ﬁbers)
to outer hair cells. Efferent nerve ﬁbers of the lateral sys-
tem contact the synapses of the radial afferents on the inner
hair cells and the medial system the outer hair cells directly
(reviewed by Raphael and Altschuler).22 Because it is hard
to verify the different bundles with whole mount material
imaging and their role for LNC transport is potentially the
same, we can simply call the nerve ﬁbers passing through the
inner tunnel of the organ of Corti ‘‘tunnel ﬁbers.’’ Tunnel
ﬁbers, together with nerve ﬁbers innervating the inner hair
cells, pass through Rosenthal’s canal. LNCs on the surface of
nerve ﬁbers can also freely diffuse between different ﬁbers
including afferent and efferent nerve ﬁbers and migrate along
the longitude of the nerve ﬁbers. The disappearance of LNCs
from the tunnel ﬁbers after long time incubation with solu-
Figure 5. Distribution of LNCs in the organ of Corti and spiral ganglion cells was demonstrated by
3D scanning. Continuing through the tunnel ﬁbers, nanoparticles reached the inner hair cells (A).
Surface plot from a single slice showed the close spatial relationship between LNCs (B. FITC
signal; C. Nile Red signal) and the nuclei of inner hair cells (D. DAPI of the nuclei). The perinuclear
localization of LNCs in the spiral ganglion cell (E) was proven by surface plot of a single slice (F,
FITC signal; G, Nile Red signal; H, DAPI signal of the nucleus). The samples were taken 24 h post-
round window membrane administration of LNCs.
Figure 6. LNCs remained in the cochlea 7 days post-transient round window membrane adminis-
tration. The LNCs were placed on the round window membrane for 30 min and then removed.
LNCs presented along the neuroﬁlaments from Rosenthal’s canal (arrow) (A) to the tunnel ﬁbers
and were in contact with hair cells (arrow) (B, C). There was also rich accumulation of LNCs in
the lateral wall (D). Scale bar 5 8.5 lm. [Color ﬁgure can be viewed in the online issue, which is
available at www.interscience.wiley.com.]
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tions indicates their surface location. The delayed distribution
of LNCs in the hair cells may come from the spiral ganglion,
the tunnel ﬁbers, and the Corti’s liquid. The gradient uptake
of LNCs from the inner hair cells to the outer hair cells (i.e.,
quicker and greater uptake in the inner hair cells than that in
the outer hair cells) suggests that LNCs chieﬂy comes from
the spiral ganglion area via Rosenthal’s canal because of
more intense innervation and a shorter distance to the inner
hair cells. We call this the ‘‘nerve pathway.’’ The recirculation
of potassium from hair cells back to endolymph mainly takes
a pathway from the supporting cells to the stria vascularis via
different channels.23 LNCs may also travel through the retro-
grade pathway from the stria vascularis to Corti’s liquid
because there is a rapid, intense uptake of LNCs in the stria
vascularis. This possible pathway seems to be much slower
than the ‘‘nerve pathway’’ because we did not ﬁnd LNCs
inside Hensen’s cells, Deiter’s cells, and outer hair cells,
while they appeared in the inner hair cells at the 30-min time
point. Our results suggest that LNC is a promising vector to
deliver drugs to the spiral ganglion cells and hair cells.
The vestibular distribution of LNCs may originate from
the spiral ligament, which was shown in MRI using Gd-
DTPA-BMA as a tracer.6 The uptake of LNCs in the spiral
ligament ﬁbrocyte type V, which is in contact with the peril-
ymph in the scala vestibule, provides evidence for this path-
way.24,25 There is a possibility that drugs can also reach the
vestibule by applying LNCs to the round window membrane.
A slower communication between different winding was
reported in the guinea pig cochlea using Gd-DTPA-BMA
enhanced MRI.6 The present data acquired from rat cochlea
using LNCs and confocal microscopy suggests a much
faster longitudinal communication. This can be explained
by different behaviors of the LNCs and a more sensitive
detection by confocal microscopy.
The distribution of LNCs in the middle ear mucosa and
stapes artery wall compromises the relative cell population
selectivity of our LNCs. This can be further overcome by
limiting the LNCs in the area of the round window. It is
easier to achieve in humans because the round window
area is much larger than that in rats.
CONCLUSIONS
This study describes the migration of LNCs through the
round window membrane and cochlear partitions, ﬁnally
reaching the inner ear cell populations. LNCs were manu-
factured by a novel phase inversion-based process. After
round window membrane administration, LNCs reached the
spiral ganglion, including the neuron and nerve ﬁbers,
organ of Corti, and lateral wall, within 30 min. The main
pathway for LNCs to reach hair cells was the ‘‘nerve path-
way,’’ that is, diffusion from perilymph in the scala tym-
pani to the spiral ganglion, continuing with nerve ﬁbers
inside Rosenthal’s canal to approach the inner hair cells
and pillar cells, and ﬁnally the outer hair cells. The ‘‘para-
cellular pathway’’ is the main approach for LNC penetra-
tion of the round window membrane. LNCs can also reach
the vestibule, middle ear mucosa, and the adjacent artery.
This suggested that LNC is a potential vector for delivery
of drugs and proteins to the spiral ganglion, hair cells, and
the lateral wall.
We are grateful to Mr. Peter Martinsson for his technical sup-
port in confocal microscopy.
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